<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2903233439
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vostifaz
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VORICONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2334.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Glenmark Pharmaceuticals Limited - Baddi" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Glenmark Pharmaceuticals Limited - Baddi
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2732]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Alpha Pharma Industry
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vostifaz Film-coated Tablets contains the active substance voriconazole.<br />Voriconazole is an antifungal medicine. It works by killing or stopping the<br />growth of the fungi that cause infections.<br />It is used for the treatment of patients (adults and children over the age<br />of 2) with:<br />&bull; invasive aspergillosis (a type of fungal infection due to Aspergillus sp),<br />&bull; candidaemia (another type of fungal infection due to Candida sp) in<br />non-neutropenic patients (patients without abnormally low white<br />blood cells count),<br />&bull; serious invasive Candida sp. infections when the fungus is resistant to<br />fluconazole (another antifungal medicine),<br />&bull; serious fungal infections caused by Scedosporium sp. or Fusarium sp.<br />(two different species of fungi).<br />Voriconazole is intended for patients with worsening, possibly life-threatening,<br />fungal infections.<br />Prevention of fungal infections in high risk bone marrow transplant recipients.<br />This product should only be taken under the supervision of a doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Vostifaz Film-coated Tablets<br />If you are allergic to Voriconazole or any of the other ingredients of<br />Voriconazole Film-coated Tablets (see section 6).<br />It is very important that you inform your doctor or pharmacist if you are<br />taking or have taken any other medicines, even those that are obtained<br />without a prescription, or herbal medicines.<br />The medicines in the following list must not be taken during your course of<br />Voriconazole treatment:<br />&bull; Terfenadine (used for allergy)<br />&bull; Astemizole (used for allergy)<br />&bull; Cisapride (used for stomach problems)<br />&bull; Pimozide (used for treating mental illness)<br />&bull; Quinidine (used for irregular heart beat)<br />&bull; Rifampicin (used for treating tuberculosis)<br />&bull; Ivabradine (used for symptoms of chronic heart failure)<br />&bull; Efavirenz (used for treating HIV) in doses of 400 mg and above once<br />daily<br />&bull; Carbamazepine (used to treat seizures)<br />&bull; Phenobarbital (used for severe insomnia and seizures)<br />&bull; Ergot alkaloids (e.g., ergotamine, dihydroergotamine; used for migraine)<br />&bull; Sirolimus (used in transplant patients)<br />&bull; Ritonavir (used for treating HIV) in doses of 400mg and more twice<br />daily<br />&bull; St. John&rsquo;s Wort (herbal supplement)<br />&bull; Naloxegol (used to treat constipation specifically caused by pain medicines,<br />called opioids, (e.g., morphine, oxycodone, fentanyl, tramadol,<br />codeine).<br />&bull; Tolvaptan (used to treat hyponatremia (low levels of sodium in your<br />blood) or to slow kidney function decline in patients with polycystic<br />kidney disease)<br />&bull; Lurasidone (used to treat depression)<br />&bull; Venetoclax (used to treat patients with chronic lymphocytic leukaemia-<br />CLL)<br />Warnings and precautions<br />Talk to your doctor, pharmacist or nurse before taking Vostifaz Film-coated<br />Tablets if:<br />&bull; you have had an allergic reaction to other azoles.<br />&bull; you are suffering from, or have ever suffered from liver disease. If<br />you have liver disease, your doctor may prescribe a lower dose of<br />Voriconazole. Your doctor should also monitor your liver function<br />while you are being treated with Vostifaz by doing blood tests.<br />&bull; you are known to have cardiomyopathy, irregular heart beat, slow<br />heart rate or an abnormality of electrocardiogram (ECG) called &lsquo;long<br />QT syndrome&rsquo;.<br />You should avoid any sunlight and sun exposure while being treated. It is<br />important to cover sun exposed areas of skin and use sunscreen with high<br />sun protection factor (SPF), as an increased sensitivity of skin to the sun&rsquo;s<br />UV rays can occur. These precautions are also applicable to children.<br />While being treated with Vostifaz Film-coated Tablets:<br />Tell your doctor immediately if you develop<br />&bull; sunburn<br />&bull; severe skin rash or blisters<br />&bull; bone pain<br />If you develop skin disorders as described above, your doctor may<br />refer you to a dermatologist, who after consultation may decide<br />that it is important for you to be seen on a regular basis. There is a<br />small chance that skin cancer could develop with long-term use of<br />Voriconazole Film-coated Tablets.<br />If you develop signs of &lsquo;adrenal insufficiency&rsquo; where the adrenal<br />glands do not produce adequate amounts of certain steroid hormones<br />such as cortisol which may lead to symptoms such as: chronic,<br />or long lasting fatigue, muscle weakness, loss of appetite, weight loss,<br />abdominal pain, please tell your doctor.<br />If you develop signs of &lsquo;Cushing&rsquo;s syndrome&rsquo; where the body produces<br />too much of the hormone cortisol which may lead to symptoms<br />such as: weight gain, fatty hump between the shoulders, a rounded<br />face, darkening of the skin on the stomach, thighs breasts, and arms,<br />thinning skin, bruising easily, high blood sugar, excessive hair growth,<br />excessive sweating, please tell your doctor.<br />Your doctor should monitor the function of your liver and kidney by doing<br />blood tests.<br />Children and adolescents<br />Vostifaz Film-coated Tablets should not be given to children younger than<br />2 years of age.<br />Other medicines and Vostifaz Film-coated Tablets<br />Please tell your doctor or pharmacist if you are taking, have recently taken<br />or might take any other medicines, including those that are obtained without<br />a prescription.<br />Some medicines, when taken at the same time as Voriconazole, may affect<br />the way Voriconazole works or Voriconazole may affect the way they work.<br />Tell your doctor if you are taking the following medicine, as treatment with<br />Voriconazole at the same time should be avoided if possible:<br />&bull; Ritonavir (used for treating HIV) in doses of 100 mg twice daily<br />&bull; Glasdegib (used for treating cancer) &ndash; if you need to use both drugs<br />your doctor will monitor your heart rhythm frequently<br />Tell your doctor if you are taking either of the following medicines, as treatment<br />with Vostifaz Film-coated Tablets at the same time should be avoided<br />if possible, and a dose adjustment of voriconazole may be required:<br />&bull; Rifabutin (used for treating tuberculosis). If you are already being<br />treated with rifabutin your blood counts and side effects to rifabutin<br />will need to be monitored.<br />&bull; Phenytoin (used to treat epilepsy). If you are already being treated<br />with phenytoin your blood concentration of phenytoin will need to<br />be monitored during your treatment with Voriconazole Film-coated<br />Tablets and your dose may be adjusted.<br />Tell your doctor if you are taking any of the following medicines, as a dose<br />adjustment or monitoring may be required to check that the medicines<br />and/ or Vostifaz Film-coated Tablets are still having the desired effect:<br />&bull; Warfarin and other anticoagulants (e.g., phenprocoumon, acenocoumarol;<br />used to slow down clotting of the blood)<br />&bull; Ciclosporin (used in transplant patients)<br />&bull; Tacrolimus (used in transplant patients)<br />&bull; Sulphonylureas (e.g., tolbutamide, glipizide, and glyburide) (used for<br />diabetes)<br />&bull; Statins (e.g., atorvastatin, simvastatin) (used for lowering cholesterol)<br />&bull; Benzodiazepines (e.g midazolam, triazolam) (used for severe insomnia<br />and stress)<br />&bull; Omeprazole (used for treating ulcers)<br />&bull; Oral contraceptives (if you take Voriconazole Film-coated Tablets<br />whilst using oral contraceptives, you may get side effects such as nausea<br />and menstrual disorders)<br />&bull; Vinca alkaloids (e.g., vincristine and vinblastine) (used in treating<br />cancer)<br />&bull; Indinavir and other HIV protease inhibitors (used for treating HIV)<br />&bull; Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, delavirdine,<br />nevirapine) (used for treating HIV) (some doses of efavirenz<br />can NOT be taken at the same time as Voriconazole Film-coated<br />Tablets)<br />&bull; Methadone (used to treat heroin addiction)<br />&bull; Tyrosine kinase inhibitors (e.g., axitinib, bosutinib, cabozantinib, ceritinib,<br />cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib,<br />ribociclib) (used for treating cancer)<br />&bull; Tretinoin (used to treat leukaemia)<br />&bull; Alfentanil and fentanyl and other short-acting opiates such as sufentanil<br />(painkillers used for surgical procedures)<br />&bull; Oxycodone and other long-acting opiates such as hydrocodone (used<br />for moderate to severe pain)<br />&bull; Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac)<br />(used for treating pain and inflammation)<br />&bull; Fluconazole (used for fungal infections)<br />&bull; Everolimus (used for treating advanced kidney cancer and in transplant<br />patients)<br />&bull; Letermovir (used for preventing cytomegalovirus (CMV) disease after<br />bone marow transplant)<br />&bull; Ivacaftor: used to treat cystic fibrosis<br />Pregnancy and breast-feeding<br />Vostifaz Film-coated Tablets must not be taken during pregnancy, unless<br />indicated by your doctor. Effective contraception must be used in women<br />of childbearing potential. Contact your doctor immediately if you become<br />pregnant while taking Voriconazole.<br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor or pharmacist for advice before<br />taking this medicine.<br />Driving and using machines<br />Vostifaz Film-coated Tablets may cause blurring of vision or uncomfortable<br />sensitivity to light. While affected, do not drive or operate any tools or machines.<br />Contact your doctor if you experience this.<br />Vostifaz Film-coated Tablets contains lactose<br />If you have been told by your doctor that you have an intolerance to some<br />sugars, tell your doctor before taking Voriconazole.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />Your doctor will determine your dose depending on your weight and the<br />type of infection you have.<br />The recommended dose for adults (including elderly patients) is as follows:</p><p><img alt="" width="432" height="164" src="data:image/png;base64,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" />Depending on your response to treatment, your doctor may increase the<br />daily dose to 300 mg twice a day.<br />The doctor may decide to decrease the dose if you have mild to moderate<br />cirrhosis.<br />Use in children and adolescents<br />The recommended dose for children and teenagers is as follows:</p><p><img alt="" width="420" height="175" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAaQAAACvCAYAAACy/KpCAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAE7GSURBVHhe7b0LXFTXuff/E7wHlJpYncEgBSJqIebIROulCWiEWm1iIIk5SQVf+L/H9KitsQLFXE5OY7ACB5OjSTV9h3BJ02gzVJMYIwbF1Es1YGKxcgkYL8jEYJRbvERg/9fal5k9M3uGkZugz9fP/jjsy9prr/Xs9axnrbWfp5/AAEEQBEHcZDzk/wmCIAjipkIKiSAIgugVkEIiCIIgegWkkAiCIIheASkkgiAIoldACokgCILoFbhc9t2vXz/5F0EQBEF0PWoV1K5CcnGY6EGoLgiCuNWwb9doyI4gCILoFZBCIgiCIHoFpJAIgiCIXgEpJIIgCKJXQAqJuIW4isqsJ9Cv3xPIqrwq7WorR1aUHvrkPWiU9twALTDnP8PSewb556qRnxAqTsIGZZSwI+7ShsY9q6Fn1/FrxS1uC4qVdIu3IK5fEOLyz8rn90aaUZIRgX5BGSgRH1wpF9UziRt7HrNdyZjzNZ5PVa725xO3NaSQiFuIwQia+TNEYj+27D/FVAFTB1UHsaVAj0VR92KYdJJrbBrQ/tBFb4IgbEK0xzFsz7qCWNMZVK0KY0fcpQ3f1V+EGeFIL24SVxQJOQthUNL1HSCf17O0lGQgqMOKUCmX66g1LWF/K8/Gnkfnfsm4onP5I/oqpJCIWwqPoOlYGAmUVtSyfv1VVO3/GAW6SEQFf4P85Ci5J69HRHI+KpsvoTwrwWK9BL2SgVd+GoNcVCM3xk8+V970yv4IxKWvYUpLOcbSWr0bZ4/wBlTZF4GMkmY5R1qoLa/rtvv0jyLuackS08f9AX+S86yPy0F5M1exCm1orsxHcoRevie3Ni6iMn81IpR8RKxGfiVThjbWTBRW73oPGQsT2dNIzxmUsRsnLNcpZXMV5iOvI07P94Vj1Q43FIOozJX7SOViFrN8GVUbnpTKWZ+ArHK1rWr3HDzPJ3bjVbv8HVfX0w1ZqERfghQScWvh4Y+ZC2fCnPcJiutPYv+W/dAtmg6vXS8hJu8emGquoKk4EUhbhuVvv4dtqTsRnH4YTcxyqXpuFZ77uwmxCBQtIUFoQnF6OBCYjuIzyv69yEl8Hjnc0hEthIdRtPZP2O2zDFVCHQqTwpjB8DAigofKGVIoQqLBW25Qi503qObL8E34CJcKU4DcP2N/cBpqxN8b8NaRi/JJjLZKbF2+DHkBG1HTyvOyCQuatmF5zAcIMJ1Ca9NhpCMbMcu3oWkBt2b4OWdgiq3G2sxGPPxOOnsa6TkrHz6LZ2MKMKWwDq01GxGQlwrjocPY+cIr2D3XhJqGbCzyGyLf2AW6aIdy2Vn+nXho4LSXUNLA8hS8Ewm/2YoTreJu63NMeRsNradgCvgAy3I8Eb/Fmr+qFSPwsbqebshCJfoSpJCIWwx52M5cgB3/7115uE6Hmn1HgaH+GDtqMLwmPYB5gWZUN/vj4bTFQOJUeOvjsP6IWRzma5fmctnaGgB9zGa2ow4Xm75Hc0keXk4bjfSM/4MwL/tXyzpkV7XK4KJB/REME3TwGj4CQ3EXQicFwneCAXNQj69LNlktEM8JSCgwY+iEsRgl3qoF548fQQG7ZsLYO+HhNRER84KB6m9QU65YIH6Iya1m+y6i0fKgynUlSJs9Ep5jYpBlZvf64u/Yp6Q/zB+TQu+Sz3eBVrk0cAtwKPwM46EbpkOAH1PU1d+iQbm/+V/ifcxpszHc0x8xWcdh/roekhqT6X9Px+qJ6HOQQiJuOaRhu1pkJr4sDdcZJiDkwcnA5VM4ff4qmo99ih3VYYiZ/G+YGJ2Kva1lMIbuxsrXD+G8nIZzWmAueBUxad8zBVOHCuPj0m7W+9+06nUg/UU8E+Yj7etqAuNkC4RtPM+ROlwuO43zLaeRn5CM/cPvQyQuoOz0t2hrPoG9Oyqgi/FB1bokpJ1dieJr0jUcj2EjmP3B6Y9RIVPYdSGI55aVmH4Vcn77GB5U0m88hWOlF8SzneOkXEQu40xxOcyNZpw8c5k9x50YrrQ8uh+L99HFM0tMtPTYlhMNX28lf5xhGHfD9UT0RUghEbce8rAdR7foIRiGDUXQ3N8gc84+xIwZAm9DFvwyX8OK4E8li4NbG6VzkLl0GkaNCsMj8UPkuYsjUGZ4rLAGfFoMUsIrkGgYifC8OkxHE0pz/heJRdUo4r34npiM9wjA3Jefw5ydMRgzYD62z/g/mBvxCF7OnIydMf7w9J6KTL/nsG3FL/GLuEUIr06EYdB85H2vFy/31E/BwljpOcfl++BF5TrRAotAxuc/xNzkJQjOYukPX459zPJyjVa5KNwJ/bk3EDZ8KhIr5sL42hOY6CkfUj+Hp3WOqE2Vv6C4ODxhX0/y5cStBfmy6yNQXRAEcath366RhUQQBEH0CkghEQRBEL0CUkgEQRBEr4AUEkEQBNErIIVEEARB9ApIIREEQRC9AlJIBEEQRK+AFBJBEATRKyCFRBAEQfQKSCERBEEQvQJyHdQH4PVAEARxq6LoGVJIfQSqC6I7Ifkibgb2ckdDdgRBEESvgBQSQRAE0SsghUQQBEH0CkghEQRBEL0CUkgEQRBEr4AUUl+kzYySnGRE9OMhn/WISM5HZeVfEecQOrsF5vxn2DnPIL94i8ZxdkZJBoJ4yOqSZnlP70AzX82V2J0RB7343FFYvecc2uRDN4w5X7M8Os9Z5McFoV9cPszynk5heWZVXruyHNpDLCcptLh164EQ7b2JlhJkBEmh1VvkXewlZNWwCxlxoaw82Ptl5kfU+1g5Rfw39pi/l07vEI2o3L0ecXqWlo08taFxz2qp/oMyUGLNVJ+HFFKf4yoqs38Dw+IvMK2wBq2tn+EFzx14/3iTfFxNf+iiN0EQNiHad4C8r6/ClGvBX7B3cirO1JgQryvA2v/4Cz63vIzNKMmIUDUOPYekPLujkWbPtCkZb9d5I1je0345dDG6aOQIAoRaE2LZn4HpxbguVCEn+m7p+O1Ky+fYFJOLurv08g7OORQYP8fkPxxCjWkpdEUv4T/+XKpSYjcmoy0lbyLm7RrcFayT98i0VeK9ddld0+HpZZBC6mu0ncL+LfuByIVYHO4LDw9fzEo1YtU0H3bwMqo2PCn1nPQJyCq/aLWQzl2Xrme0mQ9gvdiL0+PBVX9jV3HOiD17fUQEZoiNaykq81fbWmHNp6Rzno7D07zX1i8UcVnH2WumIFsH4jVsE3uIV1mvMR/JEXrr/n4sb4VbrPsiViO/stFJvhS4cv0vpM7yRf9RYzFhKNsVOALesgS3lGzCwsQi9mszYvRzmGV1TpV/6z00aS5HfnKUdB6zOJLzy9HcfBxZSk9XtNTOoTwrQbZKVL1l1nt+dWEiqtm/3Bg/tv8gxJKu2oCn1GVkY2mw8ly9G+Y2qbycl6cXwlg55KyYBT95T3vl0CNolRfvzbsrL5plob5e3uL+yix/leyIdVhqK6dZ2+3qSSk9ZXRASU+2JG3yzjeexkeOz9NmxpH1shX64CrssBVGVg1hWFWagxUzfiTv4NyN6HW/wyydF0aN9cdQ6FjV3GFpZB1kdM9nqvsqZWa1dfuHrUJpzgrM8OOVrMCso6JcPP/9YqQnTZf3KbDOatYT7N1fjT2NLJ3GPUjWO3k+V/LYbtl2H6SQ+hpt3+FiNesbjfbRbIQGTnsJJZcKkYQspH5YqeqdKVxB1c7XsHL3gzDV/BPGRePl/RLmih/jtzUn8FbIZ1geU4AphXVordmIgLxUGI98K51TG4CEkhoUJg1CburHqLDchL2QOVXih25ij7poM9btLMWJ9zcgzW8jaq8XIz1Qh8jNUWhJexZ5U95GQ+spmAI+wDLjpyh2kS8r3+Pc+28hszoE8UtmI0gug/5hz2BLejj7tQSm2t1Y6b2L5f8DBJhOobXpMNKRjZjl76HSYWzrCiq3voiYvDAUNlxhPdt7kLcsFwcOfYjU3LFIL77EnmcvVk36Gh+m7kRw+mE0seerWhXGVAODNUwrtqQjkP2LNZ1h+6dDtEUHhuMFdRmNlC0N4TpqTQ+jaO2fsLPqCj/TRXm6Qrscup/LmuV16Mi77suLVlmUH8P7SVvhx8rwejEvz8dhTAnC/uXL7OTkAC7wNGU5NU760raewrzEe0qKm48O8PucgSm2GmvX7UL5iQ+RlPYjJiOXUMzlJfLXeKSFyYb98xR/gBdWHsVc00k0GBerOgRu0HYa77+Rg2pmXS6JCrA0srYy+gEePpXO7nsPk/craCpOBNKWYfnWStfDr6J1tBWhixbggZED5Z0KgxE082eINBdgV/EFNBZ/gjxMxah/verwfEfuWOBcHtst2+6DFNItxVD4GcZD5zUcI1mnqrr0NM7LR6x8jeP7jrJT/TF21F0ImjSBXaVizixM8/XA+eNHUIASpM0eCc8xMcgy1+Pr+u+kc/xCMUE3HMNHerObVOF0ndKCqnq5+hjkwozqi63QBQSDmQ/QDzAg8e7FWBJYjwMFZpjTZmO4pz9iWK/Z/PUX2OcqXyJtrHP+F6xelo/glEysWTDWiQC3yPm/CxPG3gkPr4mImMfyUH0RTQ5vu1we5rWYPXwIxsS8DrP5Ir4bOx9pSdeRaPgB9HGv40idHx5OWwwkToW3Pg7rj5hdNxz2ZXTyuNxLHQB9zGZ2Qh0uNsnl5rQ8neFuOXQHtSh1KK9afLHvoPvyolUWV+5EwAwuJn4YYMjE3UlPYqZHFfY5yMkFNPA0RTkdiP7BdvVkmbPh8zmKdeWHmNxqsf6v6AIwQ7RQfgBD4kAkLQlC/QFnz8PlZySGBYUg1FEYndCI8uzfY1mWHilvp2ABy6M2dar3cDC8Jj2AeYH8ffnOhVzJ1lHpE0h+bDw85b1qPIKmY2FkLdLWbcSbOwqART9F0IWTDvJd//UJ5/LYbtl2H6SQ+hr9AxHxzDz25m7GBj4EIQ4tJGP9oXr5hPYYjZAHJ7OO7imcPn8BVcfK7IbGOP0xKmQKIsF639zCEHtSfN5APTyhgfkTvBKzFmfTi3Gtwsiu55zGwe2fQJdUiAaezt5UREc8gAcjddDFm1DTytNmW84qPOIyX7wRzsPSWSk4szgH76yZA52N9PaH94iRlt9S/i+g7PS3aGs+gb07KqCLmYx7RLNGjVweuqWsp3pNygufcxsXgmjWo25lzxGaux6vH7qKcdGp2NtaBmMos8BeP2RR9h7eI1iP3hVXUb09AzFp37PeZh0qjI/L+ztCe+XQ3egR6lBe2fjtIw+4KS9OyuL0P7A91wdJzMIShFrsXReNcUGhGnISZ1vWXuPt6kmplXMoeCUJaWdXovgaqzOWDnANpw8WIFeXwqyFVpbeLqyLnoWZTp+Hy08dGquOo9TxJdGAKaOsZzEroQaLC7OwZpavXQOrltGRqvfwKpqPfYod1WGImTyWneWMy/jy6CGmULhyGc4UahFTsokwJKgWPHgEIGpJNHQFLyMxk+mjqHkId3i+jZh2fGP78ui0bLsPUkh9Dh+EPZOJgvTRyJ49Bp6eYUj+eirmhbDep1sMQdDc/4uU4HzEjLkXv9p3VTVhbsUjaC5ezpyMnTH+8LSMIWstnFAxairiUiLZO2LAoHAjvp/OGwGpARN7uWI6oYh77Rzufek5zNkZgzGefB+fk/kX/F3m6zIqPsxGrtmMorWR0IvXqce1B0I/fR5iddL4fGb9TGv+vaci0+85bFsxE8Pks63w8vgNMufsY/cdJOalX9AryN8izT94BiegNPZZLPX7uzTm7jkBCaUs/aXTMEpOwUM/BQtjh9jOIdkwGP4RTyAlvIL1NkciPK8O9qP/2siT4KK1Kc1R9YvLRoHLcuhuhmqUVwY+93dXXpyUxRiufFjPnllYYprcCi0ejKiX7eVEXb7WeSJLPU1TamUUpsUtQjhvsAfNR973fPHBIHYb1lERG3RP8Tp9nBHf3rtE43mikJyiR1ZMAIb/ilka9gsLxJV3inXBZW484rbsxIepWUw5FGAtfzfltKyr4NQy+gvk+yyW7zsE3oYs+GW+hhXhd8nn8lvwxTKydcdHGPqtwumnd8tKpUkacgxMR7GRKSD5Gn4P34eisYjv0EUiyuCrUV+v4uz9Me3Io6uy7UbYwzmlncNED9Jn66K1TGC9UyEwvVi4LjQJ7CUSoEsRWA9VPoHoDdxs+WK9cCES4UJ6cZMgXC8W0gMhMKtaYFZ1F3JFYNaAwBpxofg6v026EIgwgVll8vFbhKbDQnq4rhvKr+uxlzuykIjuxUOP6Qvn4jKzmgb084Yh0w/pOYsxZRiJHmFFsjIvsB67N/oNMCBzRiZyEgwaFm1nkC2Uy8xqGtAPAww5mJH+ChKmjJCP3wq0ofHINmQW6bEo6t4uLr/uh8JP9BGoLojuhOSLuBnYyx11UwmCIIheASkkgiAIoldAConoUnqrb7ybiXaZaPkpU+2zfD0vHiCI2wJSSES3032+3voumn7KzHth3BuCP5w5BVP8nSham4o/f25VYlSOxK0OKaQ+RltlFqL6GZC8hztQuYA9yQbWw34ThU78iPFJQ3ET/cpdlr4t0M9AxAy9eN1uLf9sHC1fV+f4vlA8Hfeoyl9eOz7oHHy9HUG9g3+yRmj6RxPzYH8/xT8fP086d/Wes2h08Jf3DEtX8QggnWdNMwgREazcuE+93X+SLRK22XwzIvn1sqQnll+dm/7W2vPLB20/ZbpHsC51DnT978TYCfx7lJEY4S1/JtleOSrPJ53de5DLW1uJKt+62Dsblcu+ox7TZe/cljoS0//e1qeivW9Dl/m8nZC/fWvXi7i67r7qXH2pEVzQzmGiB7HUhfxdj/iNQUOhkKQLEWITlwrh8vcUrTUmIV5n921FrUmIhU6INJYKNaYlLK0QId50SmgVv/fQCeHph4Um+VRHrrPL+TWPC8ZPcsV0wlMKhNpL/N4QAtM/Ff7Fv+3QLRVMNXVCmTFe0Cnfk8hI33sECrGmM7b5bz0lmOJD2O8PhMNiGvz7pCssj0sFHf9dtlXjfvx7JoUzgik2UEBkumBcGy4g1iTUys8UaTzK8uIsTQi6eJNQ0yp/FxWeKRQ3ufguSim/P74prA2UnkN6JlYmZUddPI/zMpGQ88/zLe/hSHWo5FHeydAsR/GcS+w55kl1VHFFPvvGuDnvuiJbSwRTrbVWO40oA3I5KajL67r0G5FGoUIpX7GO7a65LZHfCflbLeeo6+6kphy7g73ckYXU1/Dwx8yFM2FO24A33sxHHiLxYNAVFDn4ETNr+JVrlv1kzcC8ab7w6H+Pc/9sFotF5euqgX8jb+8vbx92tOuDTsX5Exr+yWQ/dvb+tkTPx/b3O4mTlp6u4qPsGnx+ZOcvb2Z/nHCaZiDmzLsfvh5DEfzwciQhHQbvSYhbf0A1Z6Phl695GH7klr81d/zyOaH5OLJX/xeygl/C22vmszzK++2Ry3HohLEY5eGDSRHh7KlU/si6HLUn6RY5Ho80L2ax2v+2z6lFGpd/SsPr+/+Ht6uvsrSLseGp8eI+fVwOyhXrPm4LikWL/lHEPS15nZaOX9KwVNvpnYvlBYTOmMgs0DGYNMeZb8OLzEKYz9Kcj4w9B1XPwze1BaX2lcePaVngKstP3K+29uOQ8Sc5ppk80mA7SmA70uHaC/9lWy/fIlrezk/jnGZ5XoX5yOvySEE4Vu2wtxK10uqeGFykkPocgxEU9STidduQkvg6sGgeHg2f4ehHbNqXGn7l7BnmxD8bE8CCV930vTYWky0+ubR949n4ehs10bkfO3t/cpoxnCqw3cFH2TFsN9n5yxt3j7aPOps0PeA1Lhrr9p5kzzgBuSvzcOi80oBo+OUr/Qgmt/ytteeXzwk85MXSf0fCmcdQ+E4KZulsHXNqlePlstM431aPY3uLUK2bhsn3uK36bhDFk/QhHP2yTvKpxupi97EzaKypQqnuJxhZsd7Rq3RDq3z9ZVTYe303rsJTgYPZsTsx7YW9uFSYwrR9Nj6ssCst82X4JnxkPX78c0fP4M/9XOU+hyO7WlIa3Saej6EY7WMNB+HoyPYyzmxPw6rE60gp3IxfDz9o5xl8NZ5bIMeBaqvEVu6JPGAjq3d+fADSYl7E1hPcoWw1KgJWs/1M3nRqz3Tfotb3P2Vv/LnI3D8Rf6wpED3zP//WpzgielG39/59Ajzn7njht0XL2/lOlIuJ2ZXniVLsfOEV7J7LZLghG4v8hkhJWHCRVhdDCqkP4uH7AJ5eFMZ+hYlfY/9Ay+/c2YkafuXsEHtt7HwH/2z9MWpae76uFO7A+HZ849n4esv8FnMc/JNxP3aO/tG0x7ADEOHgo2w8Hpxl5y9vfQnuiGovTWWeaAiCE8oQm7kI00bJDYiWX74JMzHLLX9r7fnl49Mc9n7KnsGWgu1IzT0OFL2E2Xopz+p5Pefl+AMYMu9E5rblCO9GDxiSJ+mz2H30UxzdPRJr06NRXVGOz5hywqIQDCtjede0SDlDoLf3+j5TLzdAP4Jhgg5ew0cwlXEWpaf5/Kgau+O1/R09g+tVypvHKqrijec1phiXshNfxtrtFexANQ6c/MZSnggMwtiRaoVhRlHuOyjS3QND8EgM1Nt7Bp8OvVK8zixUcRRBscClU63YWvtDQ0MQ5DseU+cE2lnVau/fTZIl4tILPzAufiuE2lTMstS/lrfzb9EgJmZXnvt2WZ9lmD8mhVr96Um4SquLYVrPKe0cJnoQ27qQ5wzIJ5xED/nL6xl/azcH9971OqEwKUzA9HAhPDBFKDj8phCpmy6ETw9UzdnxebNr8vkMy9zMPnGewba8bOeQrHNk0rmIfVf4TOt42sssTXd80F2T5g75uQVF1jmkBg1fb0o+jX+WjsW/Kxzeyu7tTI605vAsc5Qac1HqOSpZdiR5VeYRc4VPLOV3RWgqzpTnhYtt5mckGZTngKWUGVpzcXK6fC7omjxnFrhGML2rUZ5bd6jKplQwxobYzSG1lxbNId3eNB7F1swd0C16CAbyCcdNhx7xl9cz/tZ6MyNgiIqE7mARimYYEDJ5MuYMPYiig5OxcOYEjHNp5UphPmyt2P0415FhH//Jjp7BVfOfkvXJ7zGIWWpfYlH2G1gxexrmKhbl8KlIxBK8reX93WcGnslIRHDWGrz+WX+E23gGV8UE8giwpqe2UNm5HYOPNCjlp/b+/UP5uIS2F/56NNVfBMKDMdYStVPL27kTPMdhbvIS9sy8bJZjH+wtpBtIq7PIikmTdg4TPQjVBdGddLt8daEVS57B7RBX285j5XFJ3tF3sJc7Ukh9BKoLojvpfvlqkJe/Q7wXdLFCekGFi88NXNAkDyvJaeliM4WCiq4eOG0VmsqyhVidnF+ECLHpHwsVrj4PIG4Ye7kjb999BKoLojsh+SJuBvZyRxMQBEEQRK+AFFJfpLkSuzPioLf5UI8juxJivQ4bN0C9GZcuW9TuSdRPIy/X7qirEpf37AydzJeajri/6cr7E8RNgBRSn6MZJZuS8Xadt8O3LW2V72NdWon8Vx9BF40c/iFvtPzBoVvcjeicKgg50XYfQ/Y83evwNBCxpjPikIb4Ue+ok9aPMa+XwTgwGzHL30Nld3wPQhA3AVJIfQ4vhK36G3JWzIKfvEfiAoqMRny/Zi2SLJ/zS2g7ZNVyCqrluFRxN9KeQ9ab4VqGWQIOLlm4G5ZLGmnZW1mcVg2Lg11bnmPrcLX+OLJER6l8nyqMhIPD04Pgn0WiagOeEq8PRVzWcfkZ5fTacVTrErfd37ShqWQ9Ivi9Mj5GyY262bkdcGIlSx0MVR13iC62VG+lEZF2IIV0iyBZR75Y9OgMjJT3KUhf2Ncib9c/0dj4T+zKu4b4+UNQxHvbU95GQ+spmAI+wDLjF7jDqbuRRgT89hBajWE4lroTwemH0cTOq1oVBulb95voWsbGJUsWUj/8HMcd0lqBBTZuXBitJySLw6YMinDow2zkBmeiuKkVQtUqTKr+GKm5Y5FefImVy16sCvOSru8fhhVbuOsayZKpWjUdomOigeF4oaQGhUmDkJv6MSpGRjMrkJfpddSaHkbR2j9hZzl3MWOf7y/tGpWOuL9hnPkbXln1OpCSg3d+PRJ723Wz4ybKMCIpNAe6z1K+xUZE2oEU0i0Bt47eQGnSM3hsnIYvMweHrL/A06FXcMDBKei3+NpiMdi7CGnfIevNcy1j74C1Dv2dpqXi1FHRZYptGbRgrJ3D1bp75iMt6ToSDT+w/TjSGX6hmKAbjuEjvSWFcVIJg9Geo9rT7IhMh93fMIreQW7REAQYxmHUwB+6drPjNqxhfHUVEplIiOUa9AfsOWFvXXY2jMg5tNlczzfWyGd95NSybj+MiBMnqPJRjnaoELvr1CMIltECWTF3q6V84yMifRlSSLcCLadx1FQiNay8AeZ6JHEhEiy9NXuHrA/BME7LKehPcNzBcak9zhyyMjzugv99PijI3oR3qoMQ9sAkBOb9D1L/dhahwVPxgEtnp2dxaLu9g9SO+kD4EnvdSUv84t++DB7HOHuHq98FIXrdLrRWGBGaux6vH7I8sa3DU02uonp7hpuOal3hg9H3/VTMr+hQtfEE9u6ogC5mMu6x00eI/SNM6WORtSwd2478HdvtHcJ6deS1Zw3jigxmbbKfsSbUVi7AqWftrUvFQaiWFWxvDX6FkQ7W+C6Un/jQzqHpr/FIS7aTNBUnpq9h0jGmhFVWbZhSJi6doHKuoGrna1i5+0Eml/+EcdF4aXdrhYb1/Bka+DFltECZw+x2S9kRVyMifRlSSH0OOYCWGBJBHtJJOI2nxd4028QhKtZxTt8Co2qhgL1D1mE2rk+kXltQxhnc356LEKWX5+CQldNLXMvIHsht01KHlpDhLlMcymALtvDxf4vD1Sfht3+ZeMwzOAGlsc9i6TTrE9s4PFV6xjYMhn/EE246qrXSKfc3+CGmPfMi0oPzsez1EtwV7tzNTofpljAiF3FFZ+/QNAj1BzoRRsSlE1TO1ziuFSqkplTj+eply0oeLRB/u6ArLGVN2hkR6cuwRswp7RwmepDO10Uvd8jalQ5Se8jZal/AXTc7bsmXXK6iE00b56LyccXdjlMHq1bHooh9WUhz5rDTpq7cSNOCfK7ayahNPrWcoFao0q+zBlM8fETj+ZwHFJTKWcmPOvCiLH+IE9LS4tj/vC7q5Hyy3yajRtloOCnVKkNWZ9ZNXRayE9w+IPP2ckcW0u1Cb3fI2pUOUnvI2WpfoEsdwsrlquNzSOO2wOdFe+uys2FEmDUYOgWRNg5Njfj23iUdDyPSrhPUIQjSChXiGahhPRc7HUrrLksZHRwR6auQ66A+AtUF0Z30Dvninw7EIjh1CorLV2HSsQyMN7yLmMKPsW6WvQdq4lbAXu7IQiIIopcwEPrp8xB7mVlNA/phgCEHM9JfQcKUEfJx4laHLKQ+AtUF0Z2QfBE3A7KQCIIgiF4JKSSCIAiiV0AKiSAIgugVkEIiCIIgegVOFzXwySaCIAiC6E7UKohW2fURqC6I7oTki7gZdMEqO2sMDmnTIyI5DyXteUC+AdrO5SNB9JLbybgkTmKetIf1/vORnPxE5/NBEARBtEsHFNIV1H9dz31VoPh6K5oqNmLKkWQYFr/dRZErW3D+cAGyzEtgqt1tjT3jFrKbDc1gbO6ivv82rFu3lWlwVQwcZ1CsGIIgiE7RyUUNHvAa93MkLJoJFHyM/VXfoFIdndJpBE6NmClyii0lr+Knoidc7vF3Gbte8ZDLz+XWWD4q5Yih+ogIzFBZQC0lm7AwsUi+dg4yDjHFicuo2vCkbawRrZgtYgr29x8gn8MtpBO298zarooiyjY57APEWDHO/HcRBEEQzuiCVXb94e3DXXvU4Zv9uVge8wECTKfQ2nQY6chGzHIjtm5TR+BcBu98jZgpjZJ51T9sBf5uWsJ+cQslAyH7f8/OvQemmitoKk4E0pZh+dYT4FEJzBU/xm9rTiBHdirYP+wZbOExVMRrmXU1zUfcP3DaS6pYI8dwQitmi+b9r6BW/G1Fuadx0peqKKJWJ4dirBh1PBaCIAjCLbpAIbWgqf4i+/8OXCz/DAW4CxPG3gkPr4mImMdj/rfA3yZWybvY/olGfJPvtMb76lSxSgbDa9IDmBdoRvXFJimey5xZmObbXvRL+1gj+7BDK2aL5v01kO/ZP9g+iuhV+QSCIAiiI3RaIbWZ/47svP3QxcdjeXwUInEBZae/RVuzEtFyCgwT1RE4d6JuzHjHyKE6LZNipBi0DZdP4fT5q2g+9il2VIchZnKQFJHRAWatjWgvfqIUvM29+7vAazxsooj+owEjArUirBIEQRDu0AGFNAQ+o32YqSF55PXUr8S5eRvxwZr5uHvcXLycORk7Y/zh6T0VmX7PYdsKP3xiE6vk1/jNb1LcjJkyGEGW+CpD4G3Igl/ma1gR/kP5uD2yt2Cdeg7Jnjsw3u2YLc5okWLrs2stUURn3m+NFdPdc0ht5ciK0qNfVJa4kERaFahHVFZ55yOB3rLIMXP4ohPL6suv5HpUL4JRnSfv6Z3IC3h6bL7Suro2KKOEvQGNqvliZW63Bc2WKLBsvziH3Chf38dorsTujDjobVbpsmfevV6eD2fPvHq3Kgqx0iZ0ZkHVDdB2GvkJ0hy2VB8dpYPybrk/a3eSf4unO50PGWYhOKWdw0QPYlsXrUJDYYqgQ5iQVHhGO6JmB7lenC4E2kSf7AhKlEzHyJqdpwvStkTfPKkRAVQd7bMTuIr+qcmNPpd8Po+42gVF3N67LkVElaKT8ki818S/Q4R40ynhuvhbJ0Ru3iJsVqKsXpejwEYahYo+F6iXl+0CITZpqRCufhdqtwlJKQVC7fVTgik+hJWFHIlXxHk02W5BM2Kue9i+4x2U9w7d31HG7eWOFFIfwaEulNDMT8UKT+l0Qnj6QcFcYRKSwlkjIDYckUKSqUxo0gh9HJh+SDjDXx7ddCF8uhySmqdpFxo5MP1d4V0mrLrwcGG6mMY/hQpTCntJ+XF2zySTUNH0lSTQ8jUIf0n42PQSE3glHSVMc4jwVOwCpkTZPl2skP5mkpSOLl4wljUwWS0TTEmR8jXqvKuvixf++OZK27TlBkFqMLmCrhOYthaSdFLDeV0pp6Q/CpuVF88dhTQ9XAhnaYDdP9ZYyl6lBo1nV7W0TaWCMZY3UkreVFvg40Ls47ZlVFj7nXRvpQ7U54vPVaNxvytC7eGNQqyYrzAhPJyl2SMKiYfEZvlcs1ZIUssPHheMFVeschUbKzzOFZOxjHWZNBSmQ33aywHrXFmeWd5sGkr7OjAKxqRp7FopVLc1jLhzOZVkWU5bCfEtyotG4+q00VUaVvn5RRSFJNcLS18Xmy2UNV0Xmjr8Xm4WCsSQ6lJ+pZD8/Fbq99T+edkWniKYKr61la923vEbkne7NKxpuc6/7Sa9u/y3mi5Y1EDcFDzG4bHkxcA7uXgH0Vi+cCg+Wr4MeQEbUdN6CcXpA5AW8yK2nvhOvkADcyMCfnsIrTnRYELDlxhixZZ0sN4Tk98zqFo1XZyrU1YWvhXyGZbHFGBKYR1aazYiIC8VxiNeiM6p4lIF9gYgtmgzMut/jnccVjt+i1rf/5RXO+Yic/9E/LGmQFz5+Pxbn+KI1srHBr6WUn1dFjIa5uFtddry92EeQdOxMLIWpqOncfXLozCZgerdx3CysRYVpXosirofNxRzdGA4Xig5z8pxLHITfo938rM1np0v5pFoqfjYxarLrcjZaltG63aelIZXlToQmti9rM+10nuX4/0OHcbOF17B7rkm1DRkY5HfEJ5Ct9NW+T7Wpfli0aMzYDtDOwI+3ta51+rcXPwVQzHa5w7rXEB1FU7XqQdyXMjBpo3YnLQVfkz2WC+eSeHjMD73c0k2GW2V79mVyf+g8Pwo6MwF2FV8DlX7P0YBJmMG9mrU1bdiGpIsXxPnfiPF6y6gsfgT5OFneGTqKPGc9mg7V4A3MouYDn0SUUGD5b0Kd2LaC3txqTAFyM3Ghyc+x9aOvpfGMBxL3Yng9MNg3S72PoZBLG32nq76O5Mj8T3dK7+X9qubt+KEuBTZvXdckvcaFCYNQm7qxzhxwr6sVfJuc/8zkkxLRySc5J8pchsZ1/q2kxRSn8UDwx6IwUrW6OkWReOh/tXYV2DG0AljMcrDB5Miwpm41OFig2N0fyszMG+ab/tCIK4s9MD540fYC1+CtNkj4TkmBlnmenxdb7bOJYhx/1WrIG2wXe04NDQEQb7jMXVOIMxff4F9Wisfm3kq9qskT6FWStAWD3/MXDiTKaED+Ojo5whcuxYrWWP41WdHYEIkogx3yie6iV8oJuhGQB8whv1xEge279Z49ivSuQzXqy5V8y2WMmqWy0irDlq0y/qLv1vreJg/JoX2RFjvCygyvoHSpGfw2DhWATZU4GSt9TmZhcRUSDUOnPzGOpcQGISxI9ULhlzIwSVvjJ7BP+XzwwBDJu5OehIz9coqWq0yuYb+8/4v1rCOSN6uIvyz4iQzQGYhsPWERl3JCkBeJat0YNLWbcSbOwoA/g61u2KX0Xwc2av/C1nBL+HtNfPBXgs7fgTDBB28ho9gT3oWpft2dfy97H8PHk5jnc7EqfDWx2H9EbPGe6WUi/3q5m/RIJ7s5jsuyvtwDB/pza49jn07PnUp765xlv9a8XMdV5BCugUYOnI4ho6aiAcjdbhcdhrn2+pxbG8RqnXTMHkiEzBcZsLUhMaq4yi9LF3jDA/vEeyF0aI/RoVMYU17COJ5T0zs8VQhZ9qXeCVmLc6mF+Ma73WK5w7AsHZXO6pxsvLRV2st5QAM10x7IEb7B0FXkIsN79TivrCf4MeBH+APqe+hOjQIY7w85fPc5EwpyphSrD1Zw/4IwIxH5jg+u/z9m4irVZfmTzTKyB71ClEnZf3bx6x13HgKx0ovyOd3Iy2ncdRUAnPabAyXP/6uTvwlkv8xiOWPr6itQ6Oy+vWX8fiZJX/KKtvJuMfdBay5LyAp1wdJrFcuCLXYuy4a47yUJspJmTw+S+yImNOYMky7hvglc/HgJI3zon8kpyPjEYCoJcxqKHgZiZlMH0Xdi2HyIacwZZS19N+RcOYxFL6Tglk6NxSY/+ROvJfDMC46FXtby2AMZVbz64dwXj5iRSkX+9XNBkzUXors4h1XGMyy/RONMlTJu1vY559ZSu20Cx1QSG1ortyFDMVLQcR/Y4/Fj539ShyFs31k5VIfhr1gc19+DnN2xmCM5w9gyLwTmduWI3zcdMSlhKIg4ccY/ivWEwxWBkC08dBPwcLYIWIvNSjjINT9OI8g1SpKXvfcg8XZiSz9SNZIGTAo3Ijvp/P0B7mx2lHNjax8HIy71WlbfAwyi9HwEBbpSlBUFIypIfdh0py72O9aRC6cjqAblHSd/iSMYaNgSDyNWOOLeGrB447Pbrl3O6su7zNh9Er7MrLHdoVoZv1Mx/t9/kPMTV6C4CxWx8OXY9+NDUJ2DD48U8UbJLbJw5CB6VuQ+4ffyfkLwHBDOpCyFitmT7PK4PCpSMQSvL1iZvsNvcK/r0Qit1pYr1yUATurQFP+mJAEzfwZazwZul/g6YfuRn/N85rENKwMhO9D0Uxe2E8dt6D5x/0K8gpG0ZqtFt8F3nadFYdljwNFL2G2XpLTdleWeY7r+HsprgZl+fecgIRSJhNLp0FrUNGmXCyrm3+K4fJxe1y94wqe4+dplOEN+vN0yP8s3K/57qpgguYU7cNnBFPSWqGwtkmoMS0VJ6yUyTb7lTjWudYuWrl0G9NOVRFEp+gN8iW1H/JCFXniXJdUKDTIx7ucpsNCejhf8NKN9yBcYi93HbCQ7kb0ut8xc9ULo8b6Yyh0CBzBJzH5WDPr/a1ZiyRn9mDVBjwlruEPRVzWcdYPUX/LwDbxu4WLNuv5W0oyECRqZ1e+5DqgvQmC6FVIPfcLSDR4i74hM2dkIifB4L6FdUO0ofHINmQW8QUvbgzXET1Cx+eQ2k7j/TdyUK2LxpKoAMDpShwVmis5nKwOcYK2Lzk3vHETBNG78QpBfE4p7zKLW23Os5gzrrtUhQeGzUpFrVCMdbN6YnEI4Q4dVEiNKM/+PZZl6ZHydgoW+Da6WImjQnMlh7PVIU5w6kuu6+IxEQRBED1PBxQSU0ZZz2JWQg0WF2ZhzSxfeGiuxFmIBJeB8ZSVHM5Wh1xEfdNFVB0rg+YCFPtVTYcc158QBEEQfYcbV0gtX+LD1CyYmW2zdvYYaQXG+L2IKHdciWNsZ5mgzUoOy+qQCIybFoOU8P1ICL4Pv9p3FcxuskNjVdM09z5qIwiCIHon/fjKBvm3A7zBd3GY6EGoLojuhOSLuBnYy13HFzUQBEEQRBdCCokgCILoFZBCIgiCIHoFpJAIJ7gRcKwjQcIswfFcrcAkehWWYHX8I/QorN5zTnbn04bGPaul/Taunno4WB1xy9BJhVSPkoz5lsiltwVytFZ98h700ViYbtIfuuhNcBne/XwJtmddkd3Yy67x20MXjZwOOWokbg5MuRT8BXsnp+JMjQnxugKs/Y+/4HOuZ9oq8d66bPJPSXQZnVNIjUexNfOo5LzyvORIr/NhbFWhmc92pjet6r0pW0Qyckq0XLjfAHKYA3PeJyhuvFla2LrsXdp4r/UsGstz5PDKbLPpscrObS3lwB3iXpbS0D+KuKclK0cfl4NyMeQDR93L/Upy2/R0HJ5WXD9teh3JP1WcT0YgLn2Nta5aSpARxGXhCOrt86Su0+Zy5CdHSccsYbBPOd5LdDNF3Bx4x+S/kDrLF/1HjcUE/t174Ah4e7D3qygXz3+/GOlJ06VTHSjGhqfGi/UryZZdiHMmt8n55WhWW80W2fkHzoryOQMRM9j5cW9id1aC5X3uknDZRK+jUwqp7etT+MKsx33+d3XP2F+netNt+K7+Iuu9hSO9uAlCUxlMU77AYsNvkF2pjlVzowxGwKQpCDQfwtEv24nl0G0o1gv/9usMTLHVWLtuC97blo3c4EwUN7VCqFqFMIvJcrdDED1rgLjL8E34yBpQrML5M5lrA5CguH7KuIIn9lqDhOX8cqJ8lppmlH/oLE9XUCkG5bsHpporaCpOBNKWYfnWE2LMFJt7pX6MCmp9bjLf49z7byGzOgTxS2YjCNw62orQRQvwwEhnYRh6IFgdcUvRCT2iBIYKQPAYLT9yPEyFs96Q1MsRe8Wrd8Pc9j3MR16Xe9LhWLVDtogsPadPtXvNNj1svrmwprzGY0HCQkRiP7bs/wLlDk5dL7EOu72FoXb+qvTg29BfH4AZPPjW6Uty4j2Numz9EJPLXWO0wP/h5UhCOgzekxC3/gArV/l0lwHi7AKKuXomG9dPVTh93lWQMY4XxjvN09c4zoPyDfXH2FGD4TXpAcwLVAX3s7+XTdRRomdh8lb+F6xelo/glEysWXA3mrl1VPoEkh8bD+eRpno6WB3R1+kCw8Y2jLGFtkrt3lDTz5nVw3v211FrehhFa/+EnZX/cis0s32v+fjxD5GU9iOYann64UDkajzHXhZneHj7YDRrjL/IS0GCg1NXI7baWRj/dtJJGN+RYxEaaBcZs0c5h4JXkpB2diWKr5XBGMljqfTH8HHRWLf3JCqME5C7Mg+Hzsu5cytAXFdgH3DME172eTIrjc9ohPCgfJdPMcV2Fc1KkLfJQVJIZaKXwJVRHpbOSsGZxTl4Z80c6Dwu48ujh2AWI/wOhyGxiPsKgyGhnXhn3R6sjujrdMtIm8j5E9q9oZpS2aoZAH3MZnYi28dMebdCM9v1mmv73836TzzY0w/YSzEQSUumQ+/iidqa6lm/HPimqAgHHZy62lsYRTh6TCtk9xX27jSg7maN1omMwrS4RQjnjcCg+cj7Xs/2HcH/PsXniYYgOKEMsZmLMG2U3FEYNVUjiF4XI97DPuBYFUzi3JUqTzpF3QxBkCUo3xB4G7Lgl/kaVoT/UD5O9A4uo4IPu5rNrPMYCb0nHy34BfZGfCAPGTdJncHAdBQbo+FSsnogWB3Rx2FC5RTXh68LtaYl7JzHBWPFFYH9IcSy8y2B+VrLBNZzF3TxJoFZSEJx+jwBupWCcXM8u4YH4aoTKoyPS78PH7Ge21AqGGNDBCbgQvEZnmagEGvapwrw18TSCmfXxQlpaXEszRShsKFVzJEtSv74vZpYfmqEwpRIdv5SYWvBBiESIUK86ZTALCS7IF1X5HwtEbZ+8kfreeIxGfFZeb7OyDu6n3aqiiA6BckXcTOwl7tOWEhKLPeTqKhpBu7wwWjWseG98AG8JzNuC3xetO8NrULsL55ESngFEg0jEZ5XB3F9jmdgB0Izy97CxWEDT9Zr4yt51GEoPFiWRrAeW5EU8MtzDH55bg5MHzyHmNkxGk5d/fCJXW9+5oOPaIbxbak9iQNgz+ujPbRIEARB3Didc67auAfJ43+JL9bswc748d04/qfFVVRmxSI4dQqKy1dh0rEMjDe8i5jCj7s54JZ83+eDUFi+BrOG9cxTt1sXBNEJSL6Im4G93HWuNR02GU+snIyCvJ343PL9Sk8xEPrp8xB7ORGGAf0wwJCDGemvIGHKCPl4N9F2Cvu37Idu0UMw9JAyIgiCuB2g8BN9BKoLojsh+SJuBl1rIREEQRBEF0EKiSAIgugVkEIiCIIgegWkkAiCIIheASkkgiAIolfgdJUdX/1AEARBEN2JWgXRsu8+Qo/XhfjR82yYVhajnFz93/LQu07cDGjZ961CmxlH1ithpa2hMbqGNjQWf4I88+NY/W8nkOAqrEdn6ZGQ5qqgjxTFgiB6LaSQ+iQ8WucGLFj5LywqPC8Ht5NDY3QJF1G8qwDmyJ9h5vg75H3uIjf+YqRZN1p/CmlOEIQMKaQ+zWiMHD4QXvqx8EMJTEdPy/GZ5PDjNuHJ/4A/ycEMpXDSl1TBB+UtTo5n0/hP7MqrlULTWyTkIlM089l585Gx56DTwIgtJZuwkMfHEcOCjEdEhIHlYzX2NLbIIeUlB7VtlVmI6mdActb/Wi0km4CLfF+pZoBECSXEupIHHsb9nCpom6ugj8o1PEDkdhS++YScR3Y1H6rUd7fFRhCEFqSQ+iQeGDblKayJPY1Eww/kKLAa2IQn/zP2B6ehRvy9AW8dOID3k7bCz3QG14vTEYjHYXzu59BZhutmYuFMf1lALuPM9jSsSryOlMLN+PXwg04DI/YPewZb+D4sYcfLUbj5PxEphnuvk4K6oQK7j51BY00VSnWRiLLEZlKHNL8GgVlNb4V8ph0gUUQrjPsuVCkaqe2kdtBH0SJTB4j8M6rvmsnyWIBdxRekZ8fP8MhUirZDED0NKaS+ilcI4nNKxQa5VYwCq0PgiDvsKlQdQvouhE4KhO8EA+agHl9/NwwBM5huivHDAEMm7k56EjP1A9k1quG6oMFSMkyNFOW+gyLdPTAEj8RAMYS7e4ERPYKmY2HkWew++imO7h6JtenRqK4ox2dMOYE7qB2uBMBWhzTn+VBC5GsESBTRCuN+EU2KQlIHiFQHfbRYYdYAkY1jprE81iJt3Ua8uaOA5SsaD/nyPBAE0ZOQQurz1OPz9/NZw622aNyg+lNsz/VBErM+BKEWe9dFY5wXu1pzuC4QscY/Iz04H8te/BuO7C9Ari4FhQ2t7NpdWBc9Hl7ymdxy8R4xUv7N8LgL/vf5oCB7E96pDkLYA5MQmPc/SP3bWYQG61XXqUOaN+NcfjJ+949BTNEyxctDzYtWjXquSSuMu4pRE63hshtP4VjpBbbzGk7vehUxad8jvbgOFcbHpXM9AxG1JBq6gpeRmMn0UdS9GCYdISzwDsAuZMRJQ8D9Iv4be3jsMZth1igk55ejGY0uhlp7GFo006fogEK6gD3JBlkAFYHLQ4klMF7naTuXjwRx7F+ab+gwHRRG6/3nIzn5ic7nozsQ5zp4HuXgh4dfw+JxikXjBv6TWYPNrAJmfYj1qI/D+iPncMlhuE7GZwaeyUhEcNYavP5Zf4Q7DYwohwXRcQtqDiu3gTBEMfvtYBGKZhgQMnky5gw9iKKDk+3uoQ5p7o37t9+LlOeTNAMkSmiFcVfhEaAR9HEQxkyPcQwQyfLs+1A0FnGdxocRDd0cwqRPwjoAxs8x+Q+HUGNaCl3RS/iPPx/GCcswawNT8MORFvMi3snPxvKYDxDAOhLXK9ZgYNoyLN9aqZrf6xwtJRkIcve9pkUzfQvBBdqHz0jhxHmI8eutQlOFSUgK1wmINAoVWpHEbxgl9PgSwVQrBkO/AZTw5vK1HQo13sH7Xy8W0gMhh1nvetqpqhumtcIoRCrh3eW865LyhL8mhbVTl3KId7H++aXpQiDCBGZpycf7KA6h7G8vbkS+pDrXCZHGHcJW3hbI8qLIQmzsfJbe44Kx4opFtgLTi9mbJV4tvV+6BULsUyHifXWxa4U3kyLl39lCmflfgkn+W9pU77DynsnHfhgeLkxX5K+hUEjSyfdqLROY1Szo2PFpyvVNZap0+b5/ChWmFCFc/FsnhCeZhIomRfCVdkC5V6SQUlgjWF+La0Lt4Y1CLLsf2P3Dw+U28Qxvc5RrWJop24RPNrP3RZciFDawq8U83mibdOvCy0lNJxUS/1tuoEQBPK+qYLaFpwimiotMDrLlimMbv+6SWjAihSRTGVMlEpJQy+dypVBRqjpXEZqvxDxwYZuuElbba1ljazIy4dAJ08OnC6zzy4QiXjCWsebGRjBd3V/ZeMPNXhL1PY3bBGOs9EI5bJay6Tp4ul1KU6lN/nWxmULB4b+yl4U3NGWqF88e1glR1ydChNj0j1Uvcl+klbUTKUxGbgHF2kHclq/WU4IpnsmNbqlgqvlSagvkTpjDu8s7dA4dNaWh5w38GeGSWO5MhoxfCDVyHfwmaQlLh19/Sepg2nWQpPvI772seLgSuqLcn59/iTf8rD6Nr8md0gqpnRLzfU1MR+qUSXXeWmMS4vn5mvUvt3nqfCgKL94k1DTI75LNe6885+PCZtNr8n3OS3KmysPtjr3cdWDIzp7+8PbhQxx1+GZ/rsVUb206jHRkI2a5EVu3ZSM3OBPFTa0QqpbBO5+b+WEobLjCzP97kLcsF0f4klueWtgK/N20hP3iq7QyELL/9/KQwBX5extu/p9AKzvDXPFj/LbmhMUct13htRurpvmI+wdOewkllwqRhCykfnhMHmZw5/5XwIRK3K+g3NM46Uuk5o5FevElXqJgbwnYiwf24qG2ahXCertrA9WiCL7V5jyLOVMew7raWuxyGY7eA17j45BTK10nCKXIWRUlzT/1WTwwbFYqaoXibg5/39dpRHn277EsS4+Ut1OwwHeQtPvASdRa5k7CwCwk9n8FTtZelXYxAkPHQjWzyHC+4ObSXWPcXjQDD3/MXDgT1bsP4KOjnyNw7VqsrK7CV58dgQnqVZy0aKYv0AWtSAua6vlS3DtwsfwzVsF3YcLYO+HhNRER84JZJbbA/+HlTBmkw+A9CXHr38X2T5hgiHMQQzAm5nWYzRdR/53WCHOdSogGw2vSA5gXaGZy0SSNR8+ZhWntVuxQ+BnGQ+c1HCOHsuyU7sMOnqZb99dAvmf/4PlIS7ouLruW5lCsLx9B3HowZZT1LGYl1GBxYRbWzPJljcdI1UKUb3BsbxGqdZH45dJfMFVwAWWnWWN87FPsqA5DzOSxbrqfqkZu0gsuFs2wRst7BHjfT2IgRvsHQVeQiw3v1OK+sJ/gx4Ef4A+p76E6NAhjvJVVnLRopi/QaYXUZv47svP2Qxcfj+XxUbIgfou25hPYu6MCupgpMEyMxrq9J1kFTUDuyp2oGzMezHSWvzfhgrAJ0TotcVUL/FU0W4Q7CAPkM2yxW+GlyVhM5mm6dX8XeI1H9Lpd4pLr0Nz1eP0fDRgRaCe03QrrwZWsR0S/J5BVScqQ6GZavsSHqVkwsy7n2tljpEUmQRtRP0dZiDKKWTPXmeW0FLMNv5AXowRguCEdSFmLFeHuWp6B+PfEXyPS6aIZ1mjpp2Bh7BDxk4WgjM8x1PAQFulKUFQUjKkh92HSnLvYb/uVorRopk/AGmSnaB+uEwr5xLc4Tsw3PodgEoprrwlCa61wODNWmq9hmy52o3C4Vh5nVs7N3C/U1OwXMtXzL5pjr9IYdGut+lzp+tpWeUzXYQGBen5DmUOSx5pVY9k1Nmm6uv8V+bd1Dkm6p+2Ep/Sc3whlxnjp2XtkDkmuB5cLELoaZ+XeAzhMjncX14Qa01LHerSbdxQnuO0m2CWZuWZd6MP3ifOovX+ZhKN83Sxo0czthL3cdUAhETcDh7pQJlVvFwHvMYWkpXR5B2SlEGssFZrkhkXsCFzjebIuqhFRT3Zfl373bKehY/Sed50WzdxO2MtdX56Jvr0RJ1Uhf1x6FvlxQeLwhrgpHy2KuOPX7pTj9eUfid856ZP3oF78LisUCflF+Cs/j/u8E7/xCsXTcY9KHsf1ccj4U7L0MaQ+AVnlpVKaon881YeDZ9u7rlHON0Pt0fzBVdhxWd5v8zGm8uHlJZRnJcjez/shKKMELZofbSqoJ62V459hT0asNIGdG8PKRvbtJ7op+h/kxIdgaEMNyirM0N3nj9Fab49SLzMmQtd/DCbN4fOoqsnwdsvtkl2++Oamo9pbAlo0cztDCqlPMxSjfbi7oLsRnVMlvcC1JsQWbca6nSelhR8KrvzaHfFyvP6gL5ZtXAqkJeHRXyZh59z/xu8XBEKZIpb4FrW+/ymvYMxF5v6J+GNNgbia8fm3DoBP82rj6rpiKCqprWonXlh5FHNNJ9FgXAw/ce9llc871crLt9/DttSdCE4/jCb2HFWrfoyTLlZToq0SW5cvQ17ARtS0cp98A5AWk45TD28Gs5Ck1ZI50eDD/iKyU1ZxNRZikRgzQZ5orxbnMrjiEJV7E1//qdSLTHUVTtepFYqr5y/Cofc3IM1vI2rFlZs6ZmCtwIIbneMkiD4IKaRbApWrFtHRKl+J+J2tQnLl167erHF9C3TiRCyfLAbmzLsfvg7SYruCcWhoCIJ8x2PqnECYv76ABvksR1xdV4/vxHOUZbl81eZIDAsKQSg7F6hFqdbKy2Z/PJy2GEicCm/R68TnOOZqNaV62a6HDyZFhCMQdbjY5MQSUZyy8s8Zgndj5dT/xra6SVhVxXvx10TvBch9GWu3V7CTq3Hg5DfsCWQCgzB2pFqhuHr+7/GDAGZVcQttgAGJdy/Gkpl6elGJ2wKS8z7NZaZMmOIxf4JXYtbibHoxromOVm+Q6u0a1zNL5L1NSMMCxD41hBlS76Gkmff+bxCmYJosy2JvhP4YFTLFuny46jhKxSE7PUI1V17+GyZGp2JvaxmMoUxhvF6FEa5WU6qX7bbVy0uWp2HyPaLWc87QUQgIuFP+wx4fjL7vp6rlwMpK08m4x20D50vs3f4JdEmFaOB53puK6HG0SJi4PeiAQnLiZFHE6udOHMOX90KZ47CMyROdRmxQgdKKWjSPmoq4lEhUJxowKNyI7y0fA7qJf4TD9U2f/z+88vx+RK55BRtWxiO8KAtvFJwSP0h2jwBE8GWzBQkItiyLvTE8gqKQnKJHFl8+/KsCIJg/11DV8t0h8DZkwS/zNawI/lQcUuvnOQEJpXOQufQhPGg5b5Akq2rnl3zZ7svPYc7OGIzxlP0BbluO8GG2g5ISStBBnr4/YnZORnrBSsyqfRVBfF+/QcwC+xKLst/AitnTrOkOn4pELMHbK2bewHcn0mcJ5rTZGC6mHYq49QdgtjV3CeLWhPUcnaJ9+IxgSlorFNY2WZbHKiufJFcc0uoY29VQN3G58C2CY13cjGXfRLejcoVzXfHNqPhB60baaQoIoluwl7sOWEh3I3rd7zBL54VRY/1Zf1WJw3MBRUbWu16zFknWz6htqdqAp0QP1azXl3Xczk092yJWI7/yorQqTF5ZJHn25R+snRCtLH1EBGZwT79Z25GlWGm90Rt3tzMCU554mlkg+Xj/83p5H9Hn8dBj+sK5uMys1QH9vJnl5of0nMWYMoxG14lbn45LedtpvP9GDqp10VgSFQBUvo91ab5Y9OgMO59VKgaG44WSGhQmDUJu6sc4ceI9Dd93W3HCxbiQti+5vVgVpnYucjvgAa+wZ7FX+JA9u+Szj7gVGIbx8UbU8vkjvtXmYNWccTaucwjiVqWDCsneyWIjs47eQGnSM3hsnItJYb9QTNANx/CR3kD1cezb8amG77tv0eBqvNypL7mui8dEEARB9DwdUEgaThZbTuOoqUSaiOVLVblj3MSFSHAZQGsw/Cf/RMP3nQETRUd1F1HfdBFVx8qgfA9pg70vuUPn5QMEQRBEX+TGFZKWk8XxexFRLg8xyGEYAtO3wNhOlEbP8fOszg29pyLT7zlsWxGBcdO4g8L9SAi+D7/adxXMbrJD9j7A7u0ZnIDS2GexdNoo+RhBEATRF+nHVzbIvx3gDb6Lw0QPQnVBdCckX8TNwF7uaOkOQRAE0SsghUT0OG2VWYjqZ0Dynhv13kAQxK0MKaTbgi7ylNFSgowgey8cKkQHpEGIy//K5lsyezyCposhnfN2/dPiSJUgCIIUUl9FVg7uKRnZG7jae3V3IDogVYeBdoKHFJbBbDqKLzU1G0EQtyMdU0jNR5AREYSorHI7j9JEh2grR1aUXow95J7F0IySV1eJy+tFr9CjZiBihnK97E9Q9Nt2FZVZT6Cffjoipo+SlZedd4y4v6JSHX9H9JbRXkyi65ZVjtIWhdV7zrFTFQtJWe5/Cf9Yv4DdfzX28LAPjXuQrOfH66DnHq0dwjIQBHE70wGF1IbGI9uQWTQZC2f6oXnPajko2nxklCgubOpRkjFfaqzUDi3VODRefQH27JbnlbeIZOSUmDunmD38MXPhTJjzPkGxEq/HJV4IW5EhLq8X4/acL8TmBHY9tziuSt+EofoIjp2sQ03FSegWxeLf7/EWr2yrVHnHEAQIb4ViP48LNOVtNLSegingAywztheTaAAzhjaJq2ME4QxMsdVYu24Xqhyy/gPcHzUfkeYC7Cq+gMbiT5CHn+GRqb4YOTYIgajAydqr8rkEQdzudEAhfY+vT1XBrAuC/+j++K7+ojxktAOZW49KDVnjUWzN3CHudUp7wzs3NCTVU7TJzxuO9OImCE1lME35AosNv0F2ZWca1sEImDQFgeZDOPql5mfA7TAYQTN/hkimhI5+dAC7A19A+srLqPjqGFNOwKKo+2Vf28yyscQYulOqfDkukPhRM/dknXXcjZhEraqopn5ShFV1VFQVnuNnivNFaes24s0dBSwz0XjItz8uN1zU/uCZIIjblg4opDoc54HPQoMwxhJWOBDh4WFyD79F7gnHI2nldHbsGk6bXA3vyBPgNiG21+NPzy23DklxK6teIxy1mIY6HDQPAa04Z1Xf7zTOOdyDh+5usQsXzSfhL6qGtJTw2E6sFq/xWJCwEJHYjy37v0C5g6NYpp6bj9s5gT2nmX5/fQBm4CxKT1+SE28HjzswItA6I+Qx2h/36fYje8MWVN83BQ/8eCjy/vA/+Ft1AILHSNaRaNlYYgx9ixYemvx3BzAqUgddvAk1rfLHzZa5Jmcxib7CrleSkHZ2JYqvlcHIrneKRwCilrD0Cl5GYiZXjvdimEWxByNAP1g+kSCI250OKCSZ0T7wtlx9N6IWPSkPzVSieBfvCc/DQ7qB7NggjI1xY3jHJsT2+2h4dI11SKpqGbzzNcJRN3AvrOpw0FlI/fArjHQYTtqJcn6qzT2y8eGJz1VhrPn5m7CgaRuWxxRgSmEdWms2IiAvFcYjF3kONfHw9sFo1rR+kZeCBAdHse/hxImPbZzArvTepZ3+yLEIDbSLNOoK2Su0TlHYQ+9ldaDHwaLzmDF1EiYzi2toUREORv4MM4OGyBexy4LmWrxjDLh/B2ak/A7PWuICScpUvYpOOybRGEznsY6qE2EYNB953+ulkzUZCF8x8iz7qYtElGEE+3EVtScr2N8j4HNHx0WQIIhbDNZwO0X7sDq20XWh1rSEnRcupB8+LMZx0YWHC9MRJiQVnpRiuQSuFQr/ZRKSwnVieuIWmC4UnzEJsQgUYk0n5TSWCKba68L14nQhkO9/912BKST5PvI9levFjZ3/2btyGmcEdqF8/lahosL+fmsE07sa90h7mV2vjt2kPI9yD77J6dscZ89b3CTuUceAsu6X49jw57xUJpiSIsXjuthMYWvaU/K5duk3FApJOvs4Ulb4uX2WpsNCOqsPXVKh0MD/lmP+WP4mbjp9Wr6IPou93HW8e8pDU6utHM8AaWKe98rFnrAS5vkocl5yc3hHjYe3akhqJEK0wlH7il5Y7ajAdneHk/wnW8NNt5xGfkIy9g+/D5EIQbwy6e9qnqvtHIqyt6CA5WtrwQYNR7GTcY+P2gns6/hb3V3a6X9Xj6/NgZgR8EO4He26T6AsgtHLw3V8ocRBbCmw/k0QBMHpgEKSlUNpFWps5lbkiXX2S7foIRgsAcV+jEcS3B3eUeF5t2pIaiPq57gIR22DHDrbnft5jrOGmx4wH9tn/B/MjXjE6vDVMu+jBP/zwB0+I6BDERIN3ujnOQa/PDcHpg+eQ8zsGA1HsT/Bd/J8luIEdsVvntVMv6X2JA7AB6N9rMNrtwYeGDYrFbVCMdbNkpZWeIyLxy7V3wRBEJwOOFflS5+fx/jZVVhTkYv4cTQp3Xn490KxCH4+CIXlazBLIzqodl0QRNdA8kXcDOzlrgMWEuvxTlmAleFHkff+P3G7BQ7vFtpOYf+W/XaWJUEQxO0FhZ/oI1BdEN0JyRdxM+gCC4kgCIIgup52LSSCIAiC6C7UKsilQiII4vaAhuyI3gAN2REEQRC9AlJIBEGQdUT0CkghEQRBEL0CUkgEQRBEr4AUEkEQBNErIIVEEARB9ApIIREEQRC9AlJIBEEQRC8A+P8BUOnwWiL4R3IAAAAASUVORK5CYII=" />Depending on your response to treatment, your doctor may increase or<br />decrease the daily dose.<br />&bull; Tablets must only be given if the child is able to swallow tablets.<br />Take your tablet at least one hour before, or one hour after a meal. Swallow<br />the tablet whole with some water.<br />If you or your child are taking Voriconazole Film-coated Tablets for prevention<br />of fungal infections, your doctor may stop giving Voriconazole<br />Film-coated Tablets if you or your child develop treatment related side<br />effects.<br />If you take more Vostifaz Film-coated Tablets than you should:<br />If you take more tablets than prescribed (or if someone else takes your tablets)<br />you must seek medical advice or go to the nearest hospital casualty<br />department immediately. Take your box of Voriconazole Film-coated Tablets<br />with you. You may experience abnormal intolerance to light as a result of<br />taking more Voriconazole Film-coated Tablets than you should.<br />If you forget to take Vostifaz Film-coated Tablets:<br />It is important to take your Voriconazole Film-coated Tablets regularly at the<br />same time each day. If you forget to take one dose, take your next dose when<br />it is due. Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Vostifaz Film-coated Tablets:<br />It has been shown that taking all doses at the appropriate times may greatly<br />increase the effectiveness of your medicine. Therefore unless your doctor<br />instructs you to stop treatment, it is important to keep taking Voriconazole<br />Film-coated Tablets correctly, as described above.<br />Continue taking Voriconazole Film-coated Tablets until your doctor tells<br />you to stop. Do not stop treatment early because your infection may not<br />be cured. Patients with a weakened immune system or those with difficult<br />infections may require long-term treatment to prevent the infection from<br />returning.<br />When Vostifaz Film-coated Tablets treatment is stopped by your doctor you<br />should not experience any effects.<br />If you have any further questions on the use of this medicine, ask your doctor,<br />pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody<br />gets them.<br />If any side effects occur, most are likely to be minor and temporary. However,<br />some may be serious and need medical attention.<br />Serious side effects &ndash; Stop taking Vostifaz Film-coated Tablets and see a<br />doctor immediately<br />&bull; Rash<br />&bull; Jaundice; Changes in blood tests of liver function<br />&bull; Pancreatitis<br />Other side effects<br />Very common: may affect more than 1 in 10 people<br />&bull; Visual impairment (change in vision including blurred vision, visual<br />color alterations, abnormal intolerance to visual perception of light,<br />colour blindness, eye disorder, halo vision, night blindness, swinging<br />vision, seeing sparks, visual aura, visual acuity reduced, visual brightness,<br />loss of part of the usual field of vision, spots before the eyes)<br />&bull; Fever<br />&bull; Rash<br />&bull; Nausea, vomiting, diarrhoea<br />&bull; Headache<br />&bull; Swelling of the extremities<br />&bull; Stomach pains<br />&bull; Breathing difficulties<br />&bull; Elevated liver enzymes<br />Common: may affect up to 1 in 10 people<br />&bull; Inflammation of the sinuses, inflammation of the gums, chills, weakness<br />&bull; Low numbers of some types , including severe, of red (sometimes immune-<br />related) and/or white blood cells (sometimes with fever), low<br />numbers of cells called platelets that help the blood to clot<br />&bull; Low blood sugar, low blood potassium, low sodium in the blood<br />&bull; Anxiety, depression, confusion, agitation, inability to sleep, hallucinations<br />&bull; Seizures, tremors or uncontrolled muscle movements, tingling or abnormal<br />skin sensations, increase in muscle tone, sleepiness, dizziness<br />&bull; Bleeding in the eye<br />&bull; Heart rhythm problems including very fast heartbeat, very slow<br />heartbeat, fainting<br />&bull; Low blood pressure, inflammation of a vein (which may be associated<br />with the formation of a blood clot)<br />&bull; Acute breathing difficulty, chest pain, swelling of the face (mouth, lips<br />and around eyes), fluid accumulation in the lungs<br />&bull; Constipation, indigestion, inflammation of the lips<br />&bull; Jaundice, inflammation of the liver and liver injury<br />&bull; Skin rashes which may lead to severe blistering and peeling of the<br />skin characterized by a flat, red area on the skin that is covered with<br />small confluent bumps, redness of the skin<br />&bull; Itchiness<br />&bull; Hair loss<br />&bull; Back pain<br />&bull; Kidney failure, blood in the urine, changes in kidney function test<br />Uncommon: may affect up to 1 in 100 people<br />&bull; Flu-like symptoms, irritation and inflammation of the gastrointestinal<br />tract, inflammation of the gastrointestinal tract causing antibiotic associated<br />diarrhea, inflammation of the lymphatic vessels<br />&bull; Inflammation of the thin tissue that lines the inner wall of the abdomen<br />and covers the abdominal organ<br />&bull; Enlarged lymph glands (sometimes painful), failure of blood marrow,<br />increased eosinophil<br />&bull; Depressed function of the adrenal gland, underactive thyroid gland<br />&bull; Abnormal brain function, Parkinson-like symptoms, nerve injury resulting<br />in numbness, pain, tingling or burning in the hands or feet<br />&bull; Problems with balance or coordination<br />&bull; Swelling of the brain<br />&bull; Double vision, serious conditions of the eye including: pain and inflammation<br />of the eyes and eyelids, involuntary movement of the<br />eye, abnormal eye movement, damage to the optic nerve resulting<br />in vision impairment, optic disc swelling<br />&bull; Decreased sensitivity to touch<br />&bull; Abnormal sense of taste<br />&bull; Hearing difficulties, ringing in the ears, vertigo<br />&bull; Inflammation of certain internal organs- pancreas and duodenum,<br />swelling and inflammation of the tongue<br />&bull; Enlarged liver, liver failure, gallbladder disease, gallstones<br />&bull; Joint inflammation, inflammation of the veins under the skin (which<br />may be associated with the formation of a blood clot)<br />&bull; Inflammation of the kidney, proteins in the urine, damage to the<br />kidney<br />&bull; Very fast heart rate or skipped heartbeats, sometimes with erratic<br />electrical impulses<br />&bull; Abnormal electrocardiogram (ECG)<br />&bull; Blood cholesterol increased, blood urea increased<br />&bull; Allergic skin reactions (sometimes severe), including life-threatening<br />skin condition that causes painful blisters and sores of the skin and<br />mucous membranes, especially in the mouth, inflammation of the<br />skin, hives, sunburn or severe skin reaction following exposure to<br />light or sun, skin redness and irritation, red or purple discoloration of<br />the skin which may be caused by low platelet count, eczema<br />&bull; Infusion site reaction<br />&bull; Allergic reaction or exaggerated immune response<br />Rare: may affect up to 1 in 1000 people<br />&bull; Overactive thyroid gland<br />&bull; Deterioration of brain function that is a serious complication of liver<br />disease<br />&bull; Loss of most fibres in the optic nerve, clouding of the cornea, involuntary<br />movement of the eye<br />&bull; Bullous photosensitivity<br />&bull; A disorder in which the body&rsquo;s immune system attacks part of the<br />peripheral nervous system<br />&bull; Heart rhythm or conduction problems (sometimes life threatening)<br />&bull; Life threatening allergic reaction<br />&bull; Disorder of blood clotting system<br />&bull; Allergic skin reactions (sometimes severe), including rapid swelling<br />(oedema) of the dermis, subcutaneous tissue, mucosa and submucosal<br />tissues, itchy or sore patches of thick, red skin with silvery scales<br />of skin, irritation of the skin and mucous membranes, life-threatening<br />skin condition that causes large portions of the epidermis, the skin&rsquo;s<br />outermost layer, to detach from the layers of skin below<br />&bull; Small dry scaly skin patches, sometimes thick with spikes or &lsquo;horns&rsquo;<br />Side effects with frequency not known:<br />&bull; Freckles and pigmented spots<br />Other significant side effects whose frequency is not known, but should be<br />reported to your doctor immediately:<br />&bull; Skin cancer<br />&bull; Inflammation of the tissue surrounding the bone<br />&bull; Red, scaly patches or ring-shaped skin lesions that may be a symptom<br />of an autoimmune disease called cutaneous lupus erythematosus<br />As Vostifaz Film-coated Tablets has been known to affect the liver and the<br />kidney, your doctor should monitor the function of your liver and kidney by<br />doing blood tests. Please advise your doctor if you have any stomach pains<br />or if your stools have a different consistency.<br />There have been reports of skin cancer in patients treated with Vostifaz<br />Film-coated Tablets for long periods of time.<br />Sunburn or severe skin reaction following exposure to light or sun was experienced<br />more frequently in children. If you or your child develops skin<br />disorders, your doctor may refer you to a dermatologist, who after consultation<br />may decide that it is important for you or your child to be seen on a<br />regular basis. Elevated liver enzymes were also observed more frequently<br />in children.<br />If any of these side effects persist or are troublesome, please tell your doctor.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes<br />any possible side effects not listed in this leaflet. By reporting side<br />effects you can help provide more information on the safety of this medicine.<br />&bull; To report any side effects: Saudi Arabia<br />The National Pharmacovigilance and Drug Safety Center (NCP)<br />&bull; Fax: +966-11-205-7662<br />&bull; SFDA Call Center: 19999<br />&bull; E-mail: ncp.drug@sfda.gov.sa<br />&bull; website: www.sfda.gov.sa/npc<br />&bull; other GCC States: Please contact the relevant competent<br />authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the label.<br />The expiry date refers to the last day of that month.<br />&bull; Store below 30&deg;C<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is voriconazole.<br />&bull; Other ingredients:<br />Lactose Monohydrate, Pregelatinized Starch, Croscarmelose Sodium, Povidone<br />K- 30 , Purified Water, Talc, Magnesium Stearate, Opadry II White<br />32K18425,</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vostifaz film coated tablet are White to off white oval film coated tablets,
debossed with ‘573’ on one side and G on other side. , these tablets
are packed in PVC / PVdC and Hard tempered aluminium foil blister (PVC/
PVdC-Alu) in a cardboard carton along with an Insert.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alpha Pharma,<br />King Abdullah Economic city, Kingdom of Saudi Arabia<br />Tel: +966 12 21 29013<br />Email: regulatory@alphapharma.com.sa</p><p>Manufacturing by: Glenmark For Alpha Pharma</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أقراص <strong>فوستيفاز </strong>تحتوي على المادة الفعالة فوريكونازول وهو دواء مضاد للفطريات. يعمل عن طريق قتل أو إيقاف نمو الفطريات التي تسبب العدوى.</p><p dir="RTL">يستخدم لعلاج المرضى (لبالغين والأطفال فوق سن سنتين) الذين يعانون من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء الرشاشيات الغازي (نوع من أنواع العدوى الفطرية الناجمة عن داء الرشاشيات) ،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المبيضات (نوع آخر من أنواع العدوى الفطرية الناتجة عن المبيضات) في المرضى غير المصابين بالعدلات (المرضى اللذين لا يعانون من انخفاض في عدد خلايا الدم البيضاء بشكل غر طبيعي(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المبيضات الغازية الخطيرة. الالتهابات عندما يكون الفطر مقاومًا للفلوكونازول (دواء آخر مضاد للفطريات(،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات الفطرية الخطيرة الناجمة عن البوغانة أو المغزلاوية (نوعان مختلفان من الفطريات(.</p><p dir="RTL"><strong>فوستيفاز </strong>يستخدم للمرضى الذين يعانون من الالتهابات الفطرية التي قد تهدد حياتهم، او الوقاية من الالتهابات الفطرية في متلقي زرع نخاع العظام عالية المخاطر.</p><p dir="RTL">يجب استخدام هذا المنتج فقط تحت إشراف الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إذا كنت تعاني من حساسية من الفوركينازول، أو أي من المحتويات الأخرى للقرص (المذكورة في القسم ٦).</p><p dir="RTL">من المهم أن تخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت أي أدوية أخرى ، حتى تلك التي تم الحصول عليها دون وصفة طبية ، أو أدوية عشبية.</p><p dir="RTL">يجب ألا تؤخذ الأدوية الموجودة في القائمة التالية أثناء العلاج بالفوستيفاز:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تير فينادين (يستخدم للحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استیمیزول (يستخدم للحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سیسا بريد (يستخدم المشاكل في المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيموزيد (يستخدم لعلاج الأمراض العقلية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكينيدين يستخدم لعلاج عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يستخدم لعلاج السل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفا برادين يستخدم الأعراض قصور القلب المزمن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ايفا فيرنز (يستخدم لعلاج فيروس نقص المناعة البشرية بجرعات ٤٠٠ ملغ وما فوق مرة واحدة يوميا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين (يستخدم لعلاج النوبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينوباربيتال يستخدم لعلاج الأرق والنوبات الشديدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلويدات الإرغوت على سبيل المثال الإرغوتامين ، دیهید رو جو تامين : يستخدمان العلاج الصداع النصفي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس يستخدم في مرضى زرع الأعضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونا فير (يستخدم لعلاج فيروس نقص المناعة البشرية بجرعات ٤٠٠ ملغ وأكثر مرتين يوميا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون مكملات عشبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نالوكسيغول (يستخدم لعلاج الإمساك الناجم عن أدوية الألم على وجه التحديد، وتسمى المواد الأفيونية مثل المورفين، أوكسيكودون ، فينتانیل ، ترامادول ، کودین)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولفابتان (يستخدم لعلاج نقص صوديوم الدم انخفاض مستويات الصوديوم في الدم) أو الإبطاء تدهور وظائف الكلى في المرضى الذين يعانون من مرض الكلى المتعدد الكيسات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لورا سيدون العلاج الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينيتوكلاكس (يستخدم لعلاج مرضى سرطان الدم الليمفاوي المزمن)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل أخذ أقراص فوستيفاز إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من رد فعل تحسسي تجاه الأزولات الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مرض الكبد أو عانيت منه. إذا كان لديك مرض الكبد ، قد يصف الطبيب جرعة أقل من فوستيفاز. يجب أن يراقب طبيبك أيضًا وظائف الكبد أثناء علاجك باستخدام فوستيفاز من خلال إجراء اختبارات الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تعاني من اعتلال عضلة القلب أو عدم انتظام ضربات القلب أو بطء معدل ضربات القلب أو خلل في رسم القلب الكهربائي (ECG) الذي يطلق عليه متلازمة QTC الطويلة.</p><p dir="RTL">يجب تجنب التعرض لأشعة الشمس والشمس أثناء العلاج. من المهم تغطية مناطق البشرة المعرضة للشمس واستخدام واقي من الشمس بعامل حماية عالي من أشعة الشمس(SPF) . حيث يمكن زيادة حساسية البشرة لأشعة الشمس فوق البنفسجية تنطبق هذه الاحتياطات أيضًا على الأطفال</p><p dir="RTL">أثناء تلقي العلاج باستخدام أقراص فوستيفاز:</p><p dir="RTL">أخبر طبيبك فورا إذا حدث لك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حروق الشمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي شديد أو بثور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العظام</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من اضطرابات في الجلد كما هو موضح أعلاه، فقد يحولك طبيبك إلى طبيب أمراض جلدية، والذي بعد التشاور قد يقرر أنه من المهم أن يتم رؤيتك بشكل منتظم. هناك احتمال ضئيل أن سرطان الجلد يمكن أن تتطور مع استخدام فوستيفاز على</p><p dir="RTL">المدى الطويل.</p><p dir="RTL">إذا ظهرت عليك علامات &quot; قصور الغدة الكظرية &quot; حيث لا تنتج الغدد الكظرية كميات كافية من بعض هرمونات الستيرويد مثل الكورتيزول، والتي قد تؤدي إلى أعراض مثل: التعب المزمن أو طويل الأمد . ضعف العضلات، فقدان الشهية، فقدان الوزن ، ألم في البطن ، من فضلك أخبر طبيبك.</p><p dir="RTL">إذا ظهرت عليك علامات متلازمة كوشينغ حيث ينتج الجسم الكثير من هرمون الكورتيزول الذي قد يؤدي إلى أعراض مثل:</p><p dir="RTL">زيادة الوزن ، نتوء دهني بين الكتفين ، الوجه المستدير ، سواد الجلد على البطن ، الفخذين الثديين، الذراعين ، ترقق الجلد الكدمات بسهولة ، ارتفاع نسبة السكر في الدم ، نمو الشعر الزائد، التعرق المفرط ، من فضلك أخبر طبيبك</p><p dir="RTL">يجب أن يراقب طبيبك وظيفة الكبد والكلى عن طريق إجراء اختبارات الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">يجب عدم إعطاء فوستيفاز للأطفال الذين تقل أعمارهم عن سنتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وأقراص وفوستيفاز</strong></p><p dir="RTL">يرجى إخبار طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى ، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">بعض الأدوية ، عندما تؤخذ في نفس الوقت مع فوستيفاز، قد تؤثر على الطريقة التي يعمل بها فوستيفاز أو فوستيفاز قد يؤثر على طريقة عملها. أخبر طبيبك إذا كنت تتناول الدواء التالي ، حيث يجب تجنب العلاج مع فوستيفاز في نفس الوقت إن أمكن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونا فير (يستخدم لعلاج فيروس نقص المناعة البشرية) بجرعات 100 ملجم مرتين يوميا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلاسدیجیب (يستخدم لعلاج السرطان) - إذا كنت بحاجة إلى استخدام كلا العقارين ، فسيقوم طبيبك بمراقبة نظم قلبك بشكل متكرر</p><p dir="RTL">أخير طبيباك إذا كنت تتناول أيا من الأدوية التالية، حيث يجب تجنب العلاج باستخدام فوستيفاز في نفس الوقت إن أمكن، وقد يتطلب الأمر إجراء ضبط جرعة من فوريكونازول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابوتين &nbsp;(يستخدم العلاج السل). إذا كنت تعالج بالفعل بالريفابوتين ، فسيتعين مراقبة تعداد دمك والآثار الجانبية للريفابوتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينيتوين (يستخدم لعلاج الصرع)، إذا كنت تعالج بالفعل بالفينيتوين ، فسيتعين مراقبة تركيز الفينيتوين في دمك أثناء العلاج باستخدام فوستيفاز وقد يتم ضبط الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيا من الأدوية التالية ، حيث قد تكون هناك حاجة التعديل الجرعة أو مراقبتها للتحقق من أن الأدوية و/ أو فوستيفاز لا يزال لها التأثير المطلوب:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوارفارين ومضادات التخثر الأخرى (مثل الفينبروكومون ، الأسينوكومارول : تستخدم لإبطاء تخثر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين (يستخدم في مرضى الزرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاکرولیموس ايستخدم في مرضى زرع الأعضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السلفونيل يوريا (مثل تولبوتميد، غلیبیزید، و غلیبورید) (يستخدم بمرض السكري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستاتين (على سبيل المثال ، أتورفاستاتين، سيمفاستاتين) (يستخدم لخفض الكولسترول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البنزوديازيبينات (على سبيل المثال میدازولام ، تریازولام) (يستخدم للأرق الشديد والإجهاد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اوميبرازول (يستخدم لعلاج القرحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع الحمل الفموية (إذا كنت تأخذ فوستيفاز أثناء استخدام موانع الحمل الفموية، فقد تحصل على آثار جانبية مثل الغثيان واضطرابات الدورة الشهرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلويدات فينكا (على سبيل المثال، فينكريستين والفينبلاستين) (يستخدم في علاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اندانيفير ومثبطات الأنزيم البروتيني الأخرى المستخدمة العلاج فيروس نقص المناعة البشرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات انزيم النسخ العكسي غير النوكليوسيدية (على سبيل المثال ، إيفافير ينز، دیلا فیردین ، نيفيرابين) (تستخدم لعلاج الفيروس نقص المناعة البشرية) (لا يمكن تناول بعض جرعات إيفافيرنز في نفس الوقت الذي تستخدم فيه فوستيفاز)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميثادون ايستخدم العلاج إدمان الهيروين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفنتانيل والفنتانيل وغيره من المواد الأفيونية القصيرة المفعول مثل سفنتانیل (مسكنات الألم المستخدمة في العمليات الجراحية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اوكسيكودون وغيره من المواد الأفيونية طويلة المفعول مثل الهيدروكودون (يستخدم في الألم المعتدل إلى الشديد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للالتهابات غير الستيرويدية (مثل: ايبوبروفين ، ديكلوفيناك) (تستخدم لعلاج الألم والالتهابات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفلوكونازول (يستخدم للعدوى الفطرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ايفير وليموس ايستخدم العلاج سرطان الكلى المتقدم ومرضى (زرع الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات التيروزين كينيز (على سبيل المثال، أكسيتينيب ، بوسوتينيب ، كابوزاتینیب ، سيريتينيب، كوبيميتينيب، دابرافینیپ، داساتینب، نیلوتینیب ، سونيتينيب ، إيبروتينيب ، ريبوسيكليب) (يستخدم لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتينوين (لعلاج سرطان الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليترموفير (يستخدم للوقاية من مرض الفيروس المضخم للخلايا بعد زرع نخاع العظم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفاكا فتور: يستخدم العلاج التليف الكيسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يجب ألا يستخدم فوستيفاز أثناء الحمل، إلا إذا أشار طبيبك يجب استخدام وسائل منع الحمل الفعالة في النساء ذوات إمكانية الحمل اتصل بطبيبك على الفور إذا أصبحت حاملاً اثناء علاجك بفوستیفاز.</p><p dir="RTL">إذا كنت حاملاً أو مرضعة ، واعتقدت أنك قد تكوني حاملاً أو تخططي لإنجاب طفل ، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب فوستيفاز ضبابية في الرؤية أو حساسية غير مريحة للضوء. عندما تتأثر ، لا تدفع أو تشغل أي أدوات أو آلات. أخبر طبيبك إذا حدثت لك مثل هذه الاعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أقراص فوستيفاز يحتوي على الاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك أن لديك عدم تحمل لبعض السكريات ، أخبر طبيبك قبل تناول فوستيفاز</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">خذ دائما هذا الدواء تماما كما أخبر طبيبك. استشر طبيبك إذا كنت غير متأكد.</p><p dir="RTL">سوف يحدد طبيبك الجرعة الخاصة بك اعتمادا على وزنك ونوع العدوى لديك.</p><p dir="RTL">قد يغير طبيبك الجرعة حسب حالتك.</p><p dir="RTL">الجرعة الموصى بها للبالغين (بما في ذلك المرضى المسنين) هي كما يلي:<img alt="" width="563" height="201" src="data:image/png;base64,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" /></p><p dir="RTL">بناءً على استجابتك للعلاج ، قد يزيد طبيبك الجرعة إلى 300 ملجم مرتين يوميًا.</p><p dir="RTL">قد يقرر الطبيب خفض الجرعة إذا كان لديك تليف كبدي خفيف إلى متوسط.</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong></p><p dir="RTL">الجرعة الموصى بها للأطفال والمراهقين هي كما يلي:</p><p dir="RTL"><img alt="" width="559" height="201" src="data:image/png;base64,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" /></p><p dir="RTL">بناءً على استجابتك للعلاج ، قد يزيد طبيبك أو يقلل الجرعة اليومية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأقراص يجب ان تعطى فقط اذا كان الطفل يستطيع بلعها .</p><p dir="RTL">خذ اقراص فوستيفاز قبل ساعة واحدة على الأقل من الوجبة ، أو بعد ساعة من الوجبة.</p><p dir="RTL">ابتلع القرص كاملاً مع القليل من الماء.</p><p dir="RTL">إذا كنت أنت أو طفلك تتناول أقراص فوستيفاز المغلفة بطبقة رقيقة للوقاية من الالتهابات الفطرية ، فقد يتوقف طبيبك عن إعطاء أقراص فوستيفاز إذا كنت أنت أو طفلك تعانيان من الآثار الجانبية المرتبطة بالعلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تناولت أكثر مما يجب من أقراص فوستيفاز</strong><strong> :</strong></p><p dir="RTL">إذا تناولت أقراصا أكثر من الموصوفة أو إذا تناول شخص آخر أقراصك ، فعليك طلب المشورة الطبية أو الذهاب إلى أقرب قسم إصابة في المستشفى على الفور. خذ عبوة من أقراص فوستيفاز المغلفة معك. قد تواجه عدم تحمل غير طبيعي للضوء نتيجة تناول المزيد من أقراص فوستيفاز أكثر مما ينبغي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت تناول أقراص فوستيفاز</strong></p><p dir="RTL">من المهم تناول أقراص فوستيفاز بشكل منتظم في نفس الوقت كل يوم. إذا نسيت أن تأخذ جرعة واحدة ، خذ جرعتك التالية عندما يحين موعدها. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن أخذ فوستيفاز</strong></p><p dir="RTL">لقد ثبت أن تناول جميع الجرعات في الأوقات المناسبة قد يزيد بشكل كبير من فعالية الدواء الخاص بك. لذلك ، ما لم يطلب منك طبيبك التوقف عن العلاج، فمن المهم أن تستمر في تناول أقراص فوستيفاز بشكل صحيح ، كما هو موضح أعلاه. استمر في تناول أقراص فوستيفاز حتى يخبرك طبيبك بالتوقف. لا تتوقف عن العلاج مبكرًا لأن العدوى قد لا تُشفى. قد يحتاج المرضى الذين يعانون من ضعف في جهاز المناعة أو أولئك الذين يعانون من عدوى صعبة إلى علاج طويل الأمد لمنع عودة العدوى.</p><p dir="RTL">عندما يوقف طبيبك العلاج بأقراص فوستيفاز ، يجب ألا تعاني من أي آثار.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارا جانبية ، على الرغم من عدم حصول الجميع عليها.</p><p dir="RTL">في حالة حدوث أي آثار جانبية ، فمن المرجح أن تكون بسيطة ومؤقتة. ومع ذلك ، قد يكون البعض خطير ويحتاج إلى عناية طبية.</p><p dir="RTL"><strong>آثار جانبية خطيرة - توقف عن تناول فوستيفاز واستشر الطبيب على الفور</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان تغييرات في نتائج فحص الدم لوظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL"><strong>آثار جانبية أخرى</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدا : قد تؤثر على أكثر من شخص من كل 10 أشخاص:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بصرية تغيير في الرؤية بما في ذلك الرؤية غير الواضحة ، والتغيرات البصرية في اللون، وعدم التحمل غير الطبيعي للإدراك البصري للضوء ، وعمى الألوان ، واضطراب العين ، ورؤية الهالة ، والعمى الليلي ، والرؤية المتأرجحة ، ورؤية الشرر ، والهالة البصرية ، والحد من حدة البصر ، والسطوع البصري، وفقدان البصر جزء من مجال الرؤية المعتاد والبقع أمام العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في درجة الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان ، القيء ، والإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الأطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الام المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في انزيمات الكبد</p><p dir="RTL"><strong>الآثار الجانبية الشائعة: قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجيوب الأنفية ، التهاب اللثة ، قشعريرة ، ضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنخفاض بعض الأنواع من خلايا الدم الحمراء وقد يكون شديدا وربطها في بعض الأحيان بالمناعة و / أو خلايا الدم البيضاء في بعض الأحيان مع ارتفاع في درجة الحرارة ، وأعداد منخفضة من الصفائح الدموية التي تساعد الدم على التجلط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة السكر في الدم ، انخفاض البوتاسيوم في الدم ، انخفاض الصوديوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق ، والاكتئاب ، والارتباك ، والإثارة ، وعدم القدرة على النوم ، والهلوسة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات أو الهزات أو حركات العضلات غير المنضبطة أو الإحساس بالوخز أو الإحساس غير الطبيعي بالجلد ، وزيادة في لون العضلات والنعاس والدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في ضربات القلب بما في ذلك نبضات سريعة جدا ، نبضات بطيئة جدا ، والإغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم ، التهاب الوريد الذي قد يرتبط بتكوين جلطة في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة حادة في التنفس ، ألم في الصدر ، تورم فى الوجه الفم ، الشفاه وحول العينين ، تراكم السوائل في الرئتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك وعسر الهضم والتهاب الشفتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان ، التهاب الكبد وجروح في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الذي قد يؤدي إلى ظهور تقرحات وتقرح شديد للجلد يتميز بمنطقة حمراء مسطحة على الجلد مغطاة بنتوءات صغرة متموجة ، احمرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط شعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي والدم في البول ، والتغيرات في اختبارات وظائف الكلى</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة : قد تؤثر على ما يصل إلى 1 من كل </strong><strong>۱۰۰</strong><strong> شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بالأنفلونزا ، وتهيج وإلتهابات الجهاز الهضمي ، التهاب الجهاز الهضمي مما يسبب الإسهال المرتبط بالمضادات الحيوية ، التهاب الأوعية اللمفاوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنسجة الرقيقة التي تبطن الجدار الداخلي للبطن ويغطي البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الغدد اللمفاوية مؤلمة في بعض الأحيان ، فشل نخاع الدم ، وزيادة الحمضات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وظيفة الاكتئاب للغدة الكظرية ، الغدة الدرقية الخاملة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وظائف غير طبيعية في الدماغ، وأعراض تشبه شلل الرعاش، وإصابة العصب ، مما يؤدي إلى خدر أو ألم أو وخز أو حرق في اليدين أو القدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التوازن أو التنسيق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الدماغ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرؤية المزدوجة ، والحالات الخطيرة للعين بما في ذلك: ألم التهاب العينين والجفون ، وحركة العين غير الطبيعية ، وتلف العصب البصري مما يؤدي إلى ضعف البصر ، وتورم القرص البصري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حساسية اللمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور غير طبيعي بالذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات السمع ، رنين في الأذنين ، الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بعض الأعضاء الداخلية - البنكرياس والاثني عشر ، وتورم والتهاب اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الكبد ، فشل الكبد ، مرض المرارة ، حصى في المرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل ، التهاب الأوردة تحت الجلد والتي قد تترافق مع تكوين جلطة في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى والبروتينات في البول وتلف الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدل ضربات القلب سريع للغاية أو تخطي دقات القلب ، وأحيانا مع نبضات كهربائية غير منتظمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخطيط كهربية القلب غير الطبيعي (ECG)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الكوليسترول في الدم، وزيادة اليوريا في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الجلد التحسسي الشديدة في بعض الأحيان) ، بما في ذلك حالة الجلد التي تهدد الحياة والتي تسبب تقرحات مؤلمة وتقرحات الجلد والأغشية المخاطية ، وخاصة في الفم التهاب الجلد ، خطوط الجلد ، حروق الشمس أو رد فعل الجلد الشديد بعد التعرض للضوء أو الشمس ، احمرار وتهيج الجلد ، تغير اللون الأحمر أو الأرجواني للجلد والذي قد يكون ناجما عن انخفاض عدد الصفائح الدموية ، الأكزيما</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم في موقع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي أو استجابة مناعية مبالغ فيها</p><p dir="RTL"><strong>نادر قد يؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>۱۰۰۰</strong><strong> شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور وظائف المخ التي تعد من المضاعفات الخطيرة الأمراض الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان معظم الألياف في العصب البصري ، غثيان القرنية ، حركة لا إرادية للعين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية الشديدة من الضوء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب يهاجم فيه الجهاز المناعي للجسم جزءًا من الجهاز العصبي الطرفي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نبضات القلب أو مشاكل التوصيل في بعض الأحيان تهدد الحياة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد الفعل التحسسي التي تهدد الحياة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نظام تخثر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد الفعل التحسسي للجلد الشديد في بعض الأحيان ، ويشمل التورم السريع للجلد والأنسجة تحت الجلد والأغشية المخاطية والأنسجة تحت المخاطية ، وحكة أو بقع سميكة من الجلد احمرار الجلد مع قشور فضية ، وتهيج الجلد والأغشية المخاطية ، حالة الجلد المهددة للحياة والتي تصيب أجزاء كبيرة من البشرة وتسبب انفصال الطبقة الخارجية للجلد عن طبقات الجلد الموجودة في الاسفل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع صغيرة متقشرة على الجلد ، سميكة في بعض الأحيان مع المسامير أو &laquo;قرون&raquo;</p><p dir="RTL"><strong>الآثار الجانبية التي لا يعرف ترددها</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النمش والبقع المصطبغة</p><p dir="RTL"><strong>الآثار الجانبية الأخرى المهمة التي لا يُعرف ترددها ، ولكن يجب إبلاغ طبيبك على الفور</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنسجة المحيطة بالعظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء أو متقشرة أو آفات جلدية على شكل حلقة قد تكون من أعراض مرض المناعة الذاتية الذي يسمى الذئبة الحمامية الجلدية.</p><p dir="RTL">حدثت ردود فعل أثناء الضخ بشكل غير شائع مع فوستيفاز (بما في ذلك الاحمرار وارتفاع في درجة الحرارة والتعرق وزيادة معدل ضربات القلب وضيق التنفس. قد يوقف طبيبك</p><p dir="RTL">الضخ إذا حدث ذلك.</p><p dir="RTL">نظرا لأنه من المعروف أن فوستيفاز يؤثر على الكبد والكلى ، يجب على طبيبك مراقبة وظيفة الكبد والكلى عن طريق إجراء اختبارات الدم. يرجى إبلاغ طبيبك إذا كنت تعاني من أي آلام</p><p dir="RTL">في المعدة أو إذا كان لدى البراز تناسق مختلف</p><p dir="RTL">في المرضى الذين عولجوا فوستيفاز لفترات طويلة من الزمن.</p><p dir="RTL">تعرض لحروق الشمس أو رد فعل الجلد الشديدة بعد التعرض للضوء أو الشمس كان ملاحظ</p><p dir="RTL">بشكل متكرر عند الأطفال. إذا أصيبت أنت أو طفلك باضطرابات جلدية ، فقد يحيلك طبيبك إلى طبيب أمراض جلدية ، والذي بعد التشاور قد يقرر أنه من المهم لك أو لطفلك أن يتم</p><p dir="RTL">رؤيتك بشكل منتظم. وقد لوحظت أيضا أنزيمات الكبد المرتفعة على نحو أكثر تواترا عند</p><p dir="RTL">الأطفال.</p><p dir="RTL">إذا استمرت أي من هذه الآثار الجانبية أو كانت مزعجة ، فيرجى إخبار طبيبك.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا كنت تعاني من أي آثار جانبية ، فتحدث إلى طبيبك أو الصيدلي أو الممرض. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً )انظر التفاصيل أدناه). عن طريق الإبلاغ عن الآثار الجانبية ، يمكنك المساعدة في توفر المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>للإبلاغ عن أي آثار جانبية: المملكة العربية السعودية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL"><strong>&bull; </strong><strong>الرقم الموحد: 19999</strong></p><p dir="RTL"><strong>&bull;</strong><strong>فاكس: 7662 - 205 - 11 - 966</strong><strong> +</strong></p><p dir="RTL"><strong>&bull; </strong><strong>البريد الإلكتروني:</strong><strong> </strong><strong>ncp.drug@sfda.gov.sa</strong><strong>&nbsp; </strong></p><p dir="RTL"><strong>&bull; </strong><strong>موقع الويب: </strong><strong>&nbsp;</strong><strong>www.sfda.gov.sa/npc</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دول مجلس التعاون الخليجي الأخرى: يرجى الاتصال بالسلطة المختصة</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>احفظ هذا الدواء بعيدًا عن مرأى ومدى وصول الأطفال</strong><strong>.</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور عى الملصق. يشر تاريخ انتهاء الصلاحية إلى اليوم الأخر من ذلك الشهر</strong><strong>.</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يحفظ في درجة حرارة اقل من 30 درجة مئوية</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا تتخلص من أي أدوية عن طريق مياه الرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابر سوف تساعد في حماية البيئة</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&bull;</strong><strong>المادة الفعالة : </strong>هي فوركونازول.</p><p dir="RTL"><strong>&bull;</strong><strong>المكونات أخرى: </strong>مونوهيدرات اللاكتوز ، النشا الجيلاتيني ، الصوديوم كروسكارميلوز ، بوفيدون 30 -K ، المياه النقية ، التلك ، ستيرات المغنيسيوم ، أوبادري 2 أبيض ك 1842532 .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص <strong>فوستيفاز </strong>هي أقراص مغلفة بغشاء أبيض إلى أبيض مائل للصفرة ، منقوش عليها &raquo;573&laquo; عى جانب واحد و G عى الجانب الآخر. ، هذه الاقراص معبأة في بولي كلوريد الفينيل / PVdC و رقائق الألمنيوم المقى الصلب ) PVC / PVdC-Alu ( في كرتون من الورق المقوى مع ن رة الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص <strong>فوستيفاز </strong>هي أقراص مغلفة بغشاء أبيض إلى أبيض مائل للصفرة ، منقوش عليها &raquo;573&laquo; عى جانب واحد و G عى الجانب الآخر. ، هذه الاقراص معبأة في بولي كلوريد الفينيل / PVdC و رقائق الألمنيوم المقى الصلب ) PVC / PVdC-Alu ( في كرتون من الورق المقوى مع ن رة الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vostifaz (VORICONAZOLE TABLETS  200 mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains: Voriconazole Ph.Eur 200 mg
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voriconazole, is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of invasive aspergillosis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of candidaemia in non-neutropenic patients.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of fluconazole resistant serious invasive <em>Candida </em>infections (including <em>C. krusei</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of serious fungal infections caused by <em>Scedosporium </em>spp. and <em>Fusarium </em>spp. Voriconazole should be administered primarily to patients with progressive, possibly life threatening infections.</p><p>Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy.</p><p>&nbsp;</p><p><u>Treatment</u></p><p>&nbsp;</p><p><em>Adults</em></p><p>Therapy must be initiated with the specified loading dose regimen of either intravenous or oral voriconazole to achieve plasma concentrations on Day 1 that are close to steady state. On the basis of the high oral bioavailability (96%), switching between intravenous and oral administration is appropriate when clinically indicated.</p><p>&nbsp;</p><p>Detailed information on dosage recommendations is provided in the following table:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Oral (Tablets)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Patients 40 kg and above*</em></p></td><td style="vertical-align:top"><p><em>Patients less than 40 kg</em>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading dose regimen (first 24 hours)</strong></p></td><td style="vertical-align:top"><p>400 mg every 12 hours</p></td><td style="vertical-align:top"><p>200 mg every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance dose (after first 24 hours)</strong></p></td><td style="vertical-align:top"><p>200 mg twice daily</p></td><td style="vertical-align:top"><p>100 mg twice daily</p></td></tr></tbody></table><p>* This also applies to patients aged 15 years and older</p><p>&nbsp;</p><p><em><u>Duration of treatment </u></em></p><p><em>&nbsp;</em></p><p>Treatment duration should be as short as possible depending on the patient&#39;s clinical and mycological response. Long term exposure to voriconazole greater than 180 days (6 months) requires careful assessment of the benefit-risk balance.</p><p>&nbsp;</p><p><em><u>Dosage adjustment (Adults)</u></em></p><p><em>&nbsp;</em></p><p>If patient response to treatment is inadequate, the maintenance dose may be increased to 300 mg twice daily for oral administration. For patients less than 40 kg the oral dose may be increased to 150 mg twice daily.</p><p>&nbsp;</p><p>If patient is unable to tolerate treatment at a higher dose, reduce the oral dose by 50 mg steps to the 200 mg twice daily (or 100 mg twice daily for patients less than 40 kg) maintenance dose.</p><p>&nbsp;</p><p>In case of use as prophylaxis, refer below.</p><p>&nbsp;</p><p><em>Children (2 to &lt;12 years) and young adolescents with low body weight (12 to 14 years and</em></p><p><em>&lt;50 kg)</em></p><p><em>&nbsp;</em></p><p>Voriconazole should be dosed as children as these young adolescents may metabolize voriconazole more similarly to children than to adults.</p><p>&nbsp;</p><p>The recommended dosing regimen is as follows:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Oral</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading Dose Regimen (first 24 hours)</strong></p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance Dose (after first 24 hours)</strong></p></td><td style="vertical-align:top"><p>9 mg/kg twice daily</p><p>(a maximum dose of 350 mg twice daily)</p></td></tr></tbody></table><p>Note: Based on a population pharmacokinetic analysis in 112 immunocompromised paediatric patients aged 2 to &lt;12 years and 26 immunocompromised adolescents aged 12 to &lt;17 years.</p><p>&nbsp;</p><p>It is recommended to initiate the therapy with intravenous regimen, and oral regimen should be considered only after there is a significant clinical improvement. It should be noted that an 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9 mg/kg oral dose.</p><p>&nbsp;</p><p>These oral dose recommendations for children are based on studies in which voriconazole was administered as the powder for oral suspension. Bioequivalence between the powder for oral suspension and tablets has not been investigated in a paediatric population. Considering the assumed limited gastro-enteric transit time in paediatric patients, the absorption of tablets</p><p>&nbsp;</p><p>may be different in paediatric compared to adult patients. It is therefore recommended to use the oral suspension formulation in children aged 2 to &lt;12.</p><p>&nbsp;</p><p><em>All other adolescents (12 to 14 years and &ge;50 kg; 15 to 17 years regardless of body weight)</em></p><p><em>&nbsp;</em></p><p>Voriconazole should be dosed as adults.</p><p>&nbsp;</p><p><em><u>Dosage adjustment (Children [2 to &lt;12 years] and young adolescents with low body weight</u></em><em> <u>[12 to 14 years and &lt;50 kg])</u></em></p><p><em>&nbsp;</em></p><p>If patient response to treatment is inadequate, the dose may be increased by 1 mg/kg steps (or by 50 mg steps if the maximum oral dose of 350 mg was used initially). If patient is unable to tolerate treatment, reduce the dose by 1 mg/kg steps (or by 50 mg steps if the maximum oral dose of 350 mg was used initially).</p><p>&nbsp;</p><p>Use in paediatric patients aged 2 to &lt;12 years with hepatic or renal insufficiency has not been studied.</p><p>&nbsp;</p><p><u>Prophylaxis in Adults and Children</u></p><p>&nbsp;</p><p>Prophylaxis should be initiated on the day of transplant and may be administered for up to 100 days. Prophylaxis should be as short as possible depending on the risk for developing invasive fungal infection (IFI) as defined by neutropenia or immunosuppression. It may only be continued up to 180 days after transplantation in case of continuing immunosuppression or graft versus host disease (GvHD).</p><p>&nbsp;</p><p><em>Dosage</em></p><p>The recommended dosing regimen for prophylaxis is the same as for treatment in the respective age groups. Please refer to the treatment tables above.</p><p><em>Duration of prophylaxis</em></p><p>The safety and efficacy of voriconazole use for longer than 180 days has not been adequately studied in clinical trials.</p><p>&nbsp;</p><p>Use of voriconazole in prophylaxis for greater than 180 days (6 months) requires careful assessment of the benefit-risk balance.</p><p>&nbsp;</p><p><u>The following instructions apply to both Treatment and Prophylaxis</u></p><p>&nbsp;</p><p><em>Dosage adjustment</em></p><p>For prophylaxis use, dose adjustments are not recommended in the case of lack of efficacy or treatment-related&nbsp; adverse&nbsp; events.&nbsp; In&nbsp; the&nbsp; case&nbsp; of&nbsp; treatment-related&nbsp; adverse&nbsp; events, discontinuation of voriconazole and use of alternative antifungal agents must be considered.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Dosage adjustments in case of co-administration</u></em></p><p><em>&nbsp;</em></p><p>Phenytoin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased from 200 mg to 400 mg orally, twice daily (100 mg to 200 mg orally, twice daily in patients less than 40 kg).</p><p>&nbsp;</p><p>The combination of voriconazole with rifabutin should, if possible be avoided. However, if the combination is strictly needed, the maintenance dose of voriconazole may be increased from 200 mg to 350 mg orally, twice daily (100 mg to 200 mg orally, twice daily in patients less than 40 kg).</p><p>&nbsp;</p><p>Efavirenz may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 400 mg every 12 hours and the efavirenz dose is reduced by 50%, i.e. to 300 mg once daily. When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored.</p><p>&nbsp;</p><p><em><u>Elderly</u></em><em><u> </u></em></p><p><em>&nbsp;</em></p><p>No dose adjustment is necessary for elderly patients.</p><p>&nbsp;</p><p><em><u>Renal impairment </u></em></p><p><em>&nbsp;</em></p><p>The pharmacokinetics of orally administered voriconazole are not affected by renal impairment. Therefore, no adjustment is necessary for oral dosing for patients with mild to severe renal impairment.</p><p>&nbsp;</p><p>Voriconazole is haemodialysed with a clearance of 121 ml/min. A 4- hour haemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p><em>&nbsp;</em></p><p>It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh A and B) receiving voriconazole.</p><p>&nbsp;</p><p>Voriconazole has not been studied in patients with severe chronic hepatic cirrhosis (Child- Pugh C).</p><p>&nbsp;</p><p>There is limited data on the safety of voriconazole in patients with abnormal Liver Function Tests (aspartate transaminase [AST], alanine transaminase [ALT], alkaline phosphatase [ALP], or total bilirubin &gt;5 times the upper limit of normal).</p><p>&nbsp;</p><p>Voriconazole has been associated with elevations in liver function tests and clinical signs of liver damage, such as jaundice, and must only be used in patients with severe hepatic impairment if the benefit outweighs the potential risk. Patients with severe hepatic impairment must be carefully monitored for drug toxicity.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p><em>&nbsp;</em></p><p>&nbsp;</p><p>The safety and efficacy of voriconazole in children below 2 years has not been established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Voriconazole film-coated tablets are to be taken at least one hour before, or one hour following, a meal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to voriconazole or to any of the excipients listed in section 6.1.

Coadministration with CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide or quinidine since increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes.

Coadministration with rifampicin, carbamazepine and phenobarbital since these medicinal products are likely to decrease plasma voriconazole concentrations significantly.

Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg once daily or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations.

Coadministration with high-dose ritonavir (400 mg and above twice daily) because ritonavir significantly decreases plasma voriconazole concentrations in healthy subjects at this dose.

Coadministration with ergot alkaloids (ergotamine, dihydroergotamine), which are CYP3A4 substrates, since increased plasma concentrations of these medicinal products can lead to ergotism.
Coadministration  with sirolimus  since voriconazole  is  likely to  increase plasma concentrations of sirolimus significantly.

Coadministration with St. John's Wort.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u></p><p>Caution should be used in prescribing voriconazole to patients with hypersensitivity to other azoles.</p><p>&nbsp;</p><p><u>Cardiovascular</u></p><p>Voriconazole has been associated with QTc interval prolongation. There have been rare cases of torsades de pointes in patients taking voriconazole who had risk factors, such as history of cardiotoxic chemotherapy, cardiomyopathy, hypokalaemia and concomitant medicinal products that may have been contributory. Voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital or acquired QTc-prolongation.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Cardiomyopathy, in particular when heart failure is present.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sinus bradycardia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Existing symptomatic arrhythmias.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant medicinal product that is known to prolong QTc interval. Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy. A study has been conducted in healthy volunteers which examined the effect on QTc interval of single doses of voriconazole up to 4 times the usual daily dose. No subject experienced an interval exceeding the potentially clinically-relevant threshold of 500 msec.</p><p><u>Hepatic toxicity</u></p><p>&nbsp;</p><p>In clinical trials, there have been cases of serious hepatic reactions during treatment with voriconazole (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities). Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly haematological malignancy). Transient hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors. Liver dysfunction has usually been reversible on discontinuation of therapy.</p><p><u>Monitoring of hepatic function</u></p><p>&nbsp;</p><p>Patients receiving voriconazole must be carefully monitored for hepatic toxicity. Clinical management should include laboratory evaluation of hepatic function (specifically AST and ALT) at the initiation of treatment with voriconazole and at least weekly for the first month of treatment. Treatment duration should be as short as possible; however, if based on the benefit-risk assessment the treatment is continued, monitoring frequency can be reduced to monthly if there are no changes in the liver function tests.</p><p>&nbsp;</p><p>If the liver function tests become markedly elevated, voriconazole should be discontinued, unless the medical judgment of the risk-benefit of the treatment for the patient justifies continued use.</p><p>Monitoring of hepatic function should be carried out in both children and adults. <u>Serious dermatological adverse reactions</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Phototoxicity</u></p><p>In addition voriconazole has been associated with phototoxicity including reactions such as ephelides, lentigo, actinic keratosis and pseudoporphyria. It is recommended that all patients, including children, avoid exposure to direct sunlight during voriconazole treatment and use measures such as protective clothing and sunscreen with high sun protection factor (SPF).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Squamous cell carcinoma of the skin (SCC)</u></p><p>Squamous cell carcinoma of the skin (including cutaneous SCC in situ, or Bowen&rsquo;s disease) has been reported in patients, some of whom have reported prior phototoxic reactions. If phototoxic reactions occur, multidisciplinary advice should be sought, voriconazole discontinuation and use of alternative antifungal agents should be considered and the patient should be referred to a dermatologist. If voriconazole is continued, however, dermatologic evaluation should be performed on a systematic and regular basis, to allow early detection</p><p>&nbsp;</p><p>and management of premalignant lesions.&nbsp; Voriconazole should be discontinued if premalignant skin lesions or squamous cell carcinoma are identified (see below the section under Long-term treatment).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Severe cutaneous adverse reactions</u></p><p>Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported with the use of voriconazole. If a patient develops a rash he should be monitored closely and voriconazole discontinued if lesions progress.</p><p><u>Adrenal events</u></p><p>Reversible cases of adrenal insufficiency have been reported in patients receiving azoles including voriconazole. Adrenal insufficiency has been reported in patients receiving azoles with&nbsp; or&nbsp; without&nbsp; concomitant&nbsp; corticosteroids.&nbsp; In&nbsp; patients&nbsp; receiving&nbsp; azoles&nbsp; without corticosteroids, adrenal insufficiency is related to direct inhibition of steroidogenesis by azoles. In patients taking corticosteroids, voriconazole associated CYP3A4 inhibition of their metabolism may lead to corticosteroid excess and adrenal suppression. Cushing&rsquo;s syndrome with and without subsequent adrenal insufficiency has also been reported in patients receiving voriconazole concomitantly with corticosteroids.</p><p>&nbsp;</p><p>Patients on long-term treatment with voriconazole and corticosteroids (including inhaled corticosteroids e.g., budesonide and intranasal corticosteroids) should be carefully monitored for adrenal cortex dysfunction both during treatment and when voriconazole is discontinued. Patients should be instructed to seek immediate medical care if they develop signs and symptoms of Cushing&rsquo;s syndrome or adrenal insufficiency.</p><p>&nbsp;</p><p><u>Long-term treatment</u></p><p>Long term exposure (treatment or prophylaxis) greater than 180 days (6 months) requires careful assessment of the benefit-risk balance and physicians should therefore consider the need to limit the exposure to voriconazole.</p><p>&nbsp;</p><p>Squamous cell carcinoma of the skin (SCC) (including cutaneous SCC in situ, or Bowen&rsquo;s disease) has been reported in relation with long-term voriconazole treatment.</p><p>&nbsp;</p><p>Non-infectious periostitis with elevated fluoride and alkaline phosphatase levels has been reported in transplant patients. If a patient develops skeletal pain and radiologic findings compatible with periostitis voriconazole discontinuation should be considered after multidisciplinary advice.</p><p>&nbsp;</p><p><u>Visual adverse reactions</u></p><p>There have been reports of prolonged visual adverse reactions, including blurred vision, optic neuritis and papilloedema.</p><p>&nbsp;</p><p><u>Renal adverse reactions </u></p><p>Acute renal failure has been observed in severely ill patients undergoing treatment with voriconazole. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medicinal products and have concurrent conditions that may result in decreased renal function.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Monitoring of renal function</u></p><p>Patients should be monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.</p><p>&nbsp;</p><p><u>Monitoring of pancreatic function</u></p><p>Patients, especially children, with risk factors for acute pancreatitis (e.g., recent chemotherapy, haematopoietic stem cell transplantation [HSCT]), should be monitored closely during voriconazole treatment. Monitoring of serum amylase or lipase may be considered in this clinical situation.</p><p>&nbsp;</p><p><u>Paediatric population </u></p><p>Safety and effectiveness in paediatric subjects below the age of two years has not been established. Voriconazole is indicated for paediatric patients aged two years or older. A higher frequency of liver enzyme elevations was observed in the paediatric population. Hepatic function should be monitored in both children and adults. Oral bioavailability may be limited in paediatric patients aged 2 to &lt;12 years with malabsorption and very low body weight for age. In that case, intravenous voriconazole administration is recommended.</p><p>&bull;&nbsp; Serious dermatological adverse reactions (including SCC)</p><p>The frequency of phototoxicity reactions is higher in the paediatric population. As an evolution towards SCC has been reported, stringent measures for the photoprotection are warranted in this population of patients. In children experiencing photoaging injuries such as lentigines or ephelides, sun avoidance and dermatologic follow-up are recommended even after treatment discontinuation.</p><p>&nbsp;</p><p><u>Prophylaxis</u></p><p>In case of treatment-related adverse events (hepatotoxicity, severe skin reactions including phototoxicity and SCC, severe or prolonged visual disorders and periostitis), discontinuation of voriconazole and use of alternative antifungal agents must be considered.</p><p>&nbsp;</p><p><u>Phenytoin (CYP2C9 substrate and potent CYP450 inducer)</u></p><p>Careful monitoring of phenytoin levels is recommended when phenytoin is coadministered with voriconazole. Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk.</p><p><u>Efavirenz (CYP450 inducer; CYP3A4 inhibitor and substrate)</u></p><p>When voriconazole is coadministered with efavirenz the dose of voriconazole should be increased to 400 mg every 12 hours and the dose of efavirenz should be decreased to 300 mg every 24 hours.</p><p>&nbsp;</p><p><u>Glasdegib (CYP3A4 substrate)</u></p><p>Coadministration of voriconazole is expected to increase glasdegib plasma concentrations and increase the risk of QTc prolongation. If concomitant use cannot be avoided, frequent ECG monitoring is recommended.</p><p>&nbsp;</p><p><u>Tyrosine kinase inhibitors (CYP3A4 substrate)</u></p><p>Coadministration of voriconazole with tyrosine kinase inhibitors metabolised by CYP3A4 is expected to increase tyrosine kinase inhibitor plasma concentrations and the risk of adverse reactions. If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor and close clinical monitoring is recommended.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Rifabutin (Potent CYP450 inducer)</u></p><p>Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g., uveitis) is recommended when rifabutin is coadministered with voriconazole. Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk.</p><p>&nbsp;</p><p><u>Ritonavir (potent CYP450 inducer; CYP3A4 inhibitor and substrate) </u></p><p>Coadministration of voriconazole and low-dose ritonavir (100 mg twice daily) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.</p><p>&nbsp;</p><p><u>Everolimus (CYP3A4 substrate, P-gp substrate)</u></p><p>Coadministration&nbsp; of&nbsp; voriconazole&nbsp; with&nbsp; everolimus&nbsp; is&nbsp; not&nbsp; recommended&nbsp; because voriconazole is expected to significantly increase everolimus concentrations. Currently there are insufficient data to allow dosing recommendations in this situation.</p><p>&nbsp;</p><p><u>Methadone (CYP3A4 substrate)</u></p><p>Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended when coadministered with voriconazole since methadone levels increased following coadministration of voriconazole. Dose reduction of methadone may be needed.</p><p>&nbsp;</p><p><u>Short-acting opiates (CYP3A4 substrate)</u></p><p>Reduction in the dose of alfentanil, fentanyl and other short-acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g., sufentanil) should be considered when coadministered with voriconazole. As the half-life of alfentanil is prolonged in a 4- fold manner when alfentanil is coadministered with voriconazole, and in an independent published study concomitant use of voriconazole with fentanyl resulted in an increase in the mean AUC0-&infin; of fentanyl, frequent monitoring for opiate-associated adverse reactions (including a longer respiratory monitoring period) may be necessary.</p><p><u>Long-acting opiates (CYP3A4 substrate)</u></p><p>Reduction in the dose of oxycodone and other long-acting opiates metabolized by CYP3A4 (e.g., hydrocodone) should be considered when coadministered with voriconazole. Frequent monitoring for opiate-associated adverse reactions may be necessary.</p><p>&nbsp;</p><p><u>Fluconazole (CYP2C9, CYP2C19 and CYP3A4 inhibitor)</u></p><p>Coadministration of oral voriconazole and oral fluconazole resulted in a significant increase in Cmax and AUCt&nbsp;of voriconazole in healthy subjects. The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole - associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Voriconazole tablets contain lactose and should not be given to patients with rare hereditary problems&nbsp; of&nbsp; galactose&nbsp; intolerance,&nbsp; Lapp&nbsp; lactase&nbsp; deficiency&nbsp; or&nbsp; glucose-galactose malabsorption.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="RTL">Voriconazole is metabolised by, and inhibits the activity of, cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Inhibitors or inducers of these isoenzymes may increase</p><p>&nbsp;</p><p>or decrease voriconazole plasma concentrations, respectively, and there is potential for voriconazole to increase the plasma concentrations of substances metabolised by these CYP450&nbsp; isoenzymes,&nbsp; in&nbsp; particular for substances&nbsp; metabolised&nbsp; by CYP3A4&nbsp; since voriconazole is a strong CYP3A4 inhibitor though the increase in AUC is substrate dependent (see Table below).</p><p>&nbsp;</p><p>Unless otherwise specified, drug interaction studies have been performed in healthy adult male subjects using multiple dosing to steady state with oral voriconazole at 200 mg twice daily (BID). These results are relevant to other populations and routes of administration.</p><p>&nbsp;</p><p>Voriconazole should be administered with caution in patients with concomitant medication that is known to prolong QTc interval. When there is also a potential for voriconazole to increase the plasma concentrations of substances metabolised by CYP3A4 isoenzymes (certain antihistamines, quinidine, cisapride, pimozide and ivabradine), coadministration is contraindicated.</p><p>&nbsp;</p><p><u>Interaction table</u></p><p>&nbsp;</p><p>Interactions between voriconazole and other medicinal products are listed in the table below (once daily as &ldquo;QD&rdquo;, twice daily as &ldquo;BID&rdquo;, three times daily as &ldquo;TID&rdquo; and not determined as &ldquo;ND&rdquo;). The direction of the arrow for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (&harr;), below (&darr;) or above (&uarr;) the 80-125% range. The asterisk (*) indicates a two-way interaction. AUCt, AUCt and AUC0-&infin; represent area under the curve over a dosing interval, from time zero to the time with detectable measurement and from time zero to infinity, respectively.</p><p>The interactions in the table are presented in the following order: contraindications, those requiring dose adjustment and careful clinical and/or biological monitoring, and finally those that have no significant pharmacokinetic interaction but may be of clinical interest in this therapeutic field.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Astemizole, cisapride, pimozide, quinidine, terfenadine and ivabradine</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine and long-acting barbiturates (e.g., phenobarbital, mephobarbital)</p><p><em>[potent CYP450 inducers]</em></p></td><td style="vertical-align:top"><p>Although not studied, carbamazepine and long-acting barbiturates are likely to significantly decrease plasma voriconazole concentrations.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz (a non-nucleoside reverse transcriptase inhibitor) <em>[CYP450 inducer; CYP3A4 inhibitor and substrate] </em>Efavirenz 400 mg QD, coadministered with voriconazole 200 mg BID<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Efavirenz Cmax 38%</p><p>Efavirenz AUC&nbsp; 44%</p><p>Voriconazole Cmax 61%</p><p>Voriconazole AUC 77%</p></td><td style="vertical-align:top"><p>Use of standard doses of voriconazole with efavirenz doses of 400 mg QD or higher is <strong>contraindicated.</strong></p><p>Voriconazole may be coadministered with efavirenz if the voriconazole maintenance dose is increased to 400 mg BID</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Efavirenz 300 mg QD, coadministered with voriconazole 400 mg BID<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Compared to efavirenz 600 mg QD, Efavirenz Cmax &harr;</p><p>Efavirenz AUC 17%</p><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole Cmax 23%</p><p>Voriconazole AUC&nbsp; 7%</p></td><td style="vertical-align:top"><p>and the efavirenz dose is decreased to 300 mg QD. When voriconazole treatment is stopped, the initial dose of efavirenz should be restored.</p></td></tr><tr><td style="vertical-align:top"><p>Ergot alkaloids (e.g., ergotamine and dihydroergotamine) <em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of ergot alkaloids and lead to ergotism.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p>Lurasidone [CYP3A4 substrate]</p></td><td style="vertical-align:top"><p>Although not studied,</p><p>&nbsp;</p><p>voriconazole is likely to significantly increase the plasma concentrations of lurasidone.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p>Naloxegol [CYP3A4 substrate]</p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of naloxegol.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p><p><em>[potent CYP450 inducer]</em></p><p>&nbsp;</p><p>300 mg QD</p><p>&nbsp;</p><p>300 mg QD (coadministered with voriconazole 350 mg BID)<sup>*</sup></p><p>&nbsp;</p><p>300 mg QD (coadministered with voriconazole 400 mg BID)<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Voriconazole Cmax 69%</p><p>Voriconazole AUC 78%</p><p>&nbsp;</p><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole Cmax 4%</p><p>Voriconazole AUC 32%</p><p>Rifabutin Cmax 195%</p><p>Rifabutin AUC&nbsp; 331% Compared to voriconazole 200 mg BID,</p><p>Voriconazole Cmax 104%</p><p>Voriconazole AUC 87%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk.</p><p>The maintenance dose of voriconazole may be increased to 5 mg/kg intravenously BID or from 200 mg to 350 mg orally BID (100 mg to 200 mg orally BID in patients less than 40 kg). Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g., uveitis) is recommended when rifabutin is coadministered with voriconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin (600 mg QD)</p><p><em>[potent CYP450 inducer]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax 93%</p><p>Voriconazole AUC 96%</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir (protease inhibitor) <em>[potent CYP450 inducer; CYP3A4 inhibitor and substrate] </em>High dose (400 mg BID)</p><p>&nbsp;</p><p>Low dose (100 mg BID)<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Ritonavir Cmax and AUC &harr; Voriconazole Cmax66% Voriconazole AUC 82%</p><p>Ritonavir Cmax 25%</p><p>Ritonavir AUC 13%</p><p>Voriconazole Cmax 24%</p></td><td style="vertical-align:top"><p>Coadministration of voriconazole and high doses of ritonavir (400 mg and above BID) is <strong>contraindicated.</strong></p><p>&nbsp;</p><p>Coadministration of voriconazole and low-dose ritonavir (100 mg BID) should</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Voriconazole AUC 39%</p></td><td style="vertical-align:top"><p>be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.</p></td></tr><tr><td style="vertical-align:top"><p>St. John&#39;s Wort <em>[CYP450 inducer; P-gp inducer]</em></p><p>300 mg TID (coadministered with voriconazole 400 mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>In an independent published study, Voriconazole AUC0-&infin;&darr; 59%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p>Tolvaptan</p><p><em>[CYP3A substrate</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of tolvaptan.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p>Tolvaptan</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of tolvaptan.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p>Venetoclax</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of venetoclax</p></td><td style="vertical-align:top"><p>Concomitant administration of voriconazole is <strong>contraindicated </strong>at initiation and during venetoclax dose titration phase. Dose reduction of venetoclax is required as instructed in venetoclax prescribing information during steady daily dosing; close monitoring for signs of toxicity is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole (200 mg QD)</p><p><em>[CYP2C9, CYP2C19 and</em></p><p><em>CYP3A4 inhibitor]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax 57%</p><p>Voriconazole AUC 79% Fluconazole Cmax ND Fluconazole AUC ND</p></td><td style="vertical-align:top"><p>The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole-associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p><p><em>[CYP2C9 substrate and potent CYP450 inducer]</em></p><p>300 mg QD</p><p>&nbsp;</p><p>300 mg QD (coadministered with voriconazole 400 mg BID)<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Voriconazole Cmax 49%</p><p>Voriconazole AUC 69%</p><p>Phenytoin Cmax 67%</p><p>Phenytoin AUC 81%</p></td><td style="vertical-align:top"><p>Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk. Careful monitoring of phenytoin plasma levels is recommended.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole Cmax 34%</p><p>Voriconazole AUC 39%</p></td><td style="vertical-align:top"><p>Phenytoin&nbsp;&nbsp;&nbsp; may&nbsp;&nbsp; &nbsp;be</p><p>coadministered with voriconazole if the maintenance dose of voriconazole is increased to 5 mg/kg IV BID or from 200 mg to 400 mg oral BID (100 mg to 200 mg oral BID in patients less than 40 kg)</p></td></tr><tr><td style="vertical-align:top"><p>Letermovir</p><p>[CYP2C9 and CYP2C19</p><p>inducer]</p></td><td style="vertical-align:top"><p>Voriconazole Cmax &darr; 39% Voriconazole AUC0-12 &darr; 44% Voriconazole C12 &darr; 51%</p></td><td style="vertical-align:top"><p>If concomitant administration of voriconazole with letermovir cannot be avoided, monitor for loss of voriconazole effectiveness.</p></td></tr><tr><td style="vertical-align:top"><p>Glasdegib</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of glasdegib and increase risk of QTc prolongation.</p></td><td style="vertical-align:top"><p>If concomitant use cannot be avoided, frequent ECG monitoring is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Tyrosine kinase inhibitors (e.g., axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib)</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole may increase plasma concentrations of tyrosine kinase inhibitors metabolised by CYP3A4.</p></td><td style="vertical-align:top"><p>If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Anticoagulants</p><p>Warfarin (30 mg single dose, co- administered with 300 mg BID voriconazole)</p><p><em>[CYP2C9 substrate]</em></p><p>Other oral coumarins</p><p>(e.g., phenprocoumon, acenocoumarol)</p><p><em>[CYP2C9&nbsp;&nbsp; and&nbsp;&nbsp; CYP3A4</em></p><p><em>substrates]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Maximum increase in prothrombin time was approximately 2-fold.</p><p>&nbsp;</p><p>Although not studied, voriconazole may increase the plasma concentrations of coumarins that may cause an increase in prothrombin time.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Close monitoring of prothrombin time or other suitable anticoagulation tests is recommended, and the dose of anticoagulants should be adjusted accordingly.</p></td></tr><tr><td style="vertical-align:top"><p>Ivacaftor</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of ivacaftor with risk of increased adverse reactions.</p></td><td style="vertical-align:top"><p>Dose reduction of ivacaftor is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Benzodiazepines</p><p><em>[CYP3A4 substrates]</em></p><p>&nbsp;</p><p>Midazolam (0.05 mg/kg IV single dose)</p><p>Midazolam (7.5 mg oral single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>In an independent published study, Midazolam AUC0-&yen; 3.7-fold</p></td><td style="vertical-align:top"><p>Dose reduction of benzodiazepines should be considered.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Other benzodiazepines (e.g., triazolam, alprazolam)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>In an independent published study, Midazolam Cmax 3.8-fold Midazolam AUC0-&yen; 10.3-fold</p><p>&nbsp;</p><p>Although not studied, voriconazole is likely to increase the plasma concentrations</p><p>of other benzodiazepines that are metabolised by CYP3A4 and lead to a prolonged sedative effect.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immunosuppressants</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sirolimus (2 mg single dose)</p></td><td style="vertical-align:top"><p>In an independent published study, Sirolimus Cmax 6.6-fold</p><p>Sirolimus AUC0-&infin; 11-fold</p></td><td style="vertical-align:top"><p>Coadministration of voriconazole and sirolimus is <strong>contraindicated.</strong></p></td></tr><tr><td style="vertical-align:top"><p>Everolimus</p><p><em>[also P gP substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of everolimus.</p></td><td style="vertical-align:top"><p>Coadministration of voriconazole and everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations.</p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin (in stable renal transplant recipients receiving chronic ciclosporin therapy)</p></td><td style="vertical-align:top"><p>Ciclosporin Cmax 13%</p><p>Ciclosporin AUC 70%</p></td><td style="vertical-align:top"><p>When initiating voriconazole in patients already on ciclosporin it is recommended that the ciclosporin dose be halved and ciclosporin level carefully monitored. Increased ciclosporin levels have been associated with nephrotoxicity. <u>When</u> <u>voriconazole is discontinued,</u> <u>ciclosporin levels must be</u> <u>carefully monitored and the dose</u> <u>increased as necessary</u>.</p></td></tr><tr><td style="vertical-align:top"><p>Tacrolimus (0.1 mg/kg single dose)</p></td><td style="vertical-align:top"><p>Tacrolimus Cmax 117%</p><p>Tacrolimus AUC 221%</p></td><td style="vertical-align:top"><p>When initiating voriconazole in patients already on tacrolimus, it is recommended that the tacrolimus dose be reduced to a third of the original dose and tacrolimus level carefully monitored. Increased tacrolimus</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>levels have been associated with nephrotoxicity. <u>When</u> <u>voriconazole is discontinued,</u> <u>tacrolimus levels must be</u> <u>carefully monitored and the dose</u> <u>increased as necessary</u>.</p></td></tr><tr><td style="vertical-align:top"><p>Long-Acting Opiates</p><p><em>[CYP3A4 substrates]</em></p><p>Oxycodone (10 mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>In an independent published study, Oxycodone Cmax 1.7-fold Oxycodone AUC0-&infin; 3.6-fold</p></td><td style="vertical-align:top"><p>Dose reduction in oxycodone and other long-acting opiates metabolized by CYP3A4 (e.g., hydrocodone) should be considered. Frequent monitoring for opiate-associated adverse reactions may be necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Methadone (32-100 mg QD)</p></td><td style="vertical-align:top"><p>R-methadone (active) Cmax 31%</p></td><td style="vertical-align:top"><p>Frequent monitoring for adverse</p></td></tr><tr><td style="vertical-align:top"><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>R-methadone (active) AUC 47%</p></td><td style="vertical-align:top"><p>reactions and toxicity related to</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>S-methadone Cmax 65%</p></td><td style="vertical-align:top"><p>methadone,&nbsp; including&nbsp; QTc</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>S-methadone AUC 103%</p></td><td style="vertical-align:top"><p>prolongation, is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dose reduction of methadone</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Non-Steroidal Anti- Inflammatory Drugs (NSAIDs) <em>[CYP2C9 substrates] </em>Ibuprofen (400 mg single dose)</p><p>&nbsp;</p><p>Diclofenac (50 mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>S-Ibuprofen Cmax 20%</p><p>S-Ibuprofen AUC0-&infin; 100%</p><p>Diclofenac Cmax 114%</p><p>Diclofenac AUC0-&infin; 78%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Frequent monitoring for adverse reactions and toxicity related to NSAIDs is recommended. Dose reduction of NSAIDs may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Omeprazole (40 mg QD)<sup>*</sup></p></td><td style="vertical-align:top"><p>Omeprazole Cmax 116%</p></td><td style="vertical-align:top"><p>No&nbsp; dose&nbsp; adjustment&nbsp; of</p></td></tr><tr><td style="vertical-align:top"><p><em>[CYP2C19 inhibitor; CYP2C19</em></p></td><td style="vertical-align:top"><p>Omeprazole AUC 280%</p></td><td style="vertical-align:top"><p>voriconazole is recommended.</p></td></tr><tr><td style="vertical-align:top"><p><em>and CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax 15%</p></td><td style="vertical-align:top"><p>When initiating voriconazole in</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Voriconazole AUC 41%</p></td><td style="vertical-align:top"><p>patients&nbsp; already&nbsp; receiving</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Other proton pump inhibitors that</p></td><td style="vertical-align:top"><p>omeprazole doses of 40 mg or</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>are CYP2C19 substrates may also</p></td><td style="vertical-align:top"><p>above, it is recommended that</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>be inhibited by voriconazole and</p></td><td style="vertical-align:top"><p>the omeprazole dose be halved.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>may result in increased plasma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>concentrations of these medicinal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>products.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Oral Contraceptives<sup>*</sup></p></td><td style="vertical-align:top"><p>Ethinylestradiol Cmax 36%</p></td><td style="vertical-align:top"><p>Monitoring for adverse reactions</p></td></tr><tr><td style="vertical-align:top"><p><em>[CYP3A4 substrate; CYP2C19</em></p></td><td style="vertical-align:top"><p>Ethinylestradiol AUC 61%</p></td><td style="vertical-align:top"><p>related to oral contraceptives, in</p></td></tr><tr><td style="vertical-align:top"><p><em>inhibitor]</em></p></td><td style="vertical-align:top"><p>Norethisterone Cmax 15%</p></td><td style="vertical-align:top"><p>addition&nbsp;&nbsp; to&nbsp;&nbsp; those&nbsp;&nbsp; for</p></td></tr><tr><td style="vertical-align:top"><p>Norethisterone/ethinylestradiol</p></td><td style="vertical-align:top"><p>Norethisterone AUC 53%</p></td><td style="vertical-align:top"><p>voriconazole, is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>(1 mg/0.035 mg QD)</p></td><td style="vertical-align:top"><p>Voriconazole Cmax 14%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Voriconazole AUC 46%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Short-acting Opiates</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dose reduction of alfentanil,</p></td></tr><tr><td style="vertical-align:top"><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fentanyl and other short-acting</p></td></tr><tr><td style="vertical-align:top"><p>Alfentanil (20 &mu;g/kg single</p></td><td style="vertical-align:top"><p>In an independent published study,</p></td><td style="vertical-align:top"><p>opiates similar in structure to</p></td></tr><tr><td style="vertical-align:top"><p>dose, with concomitant</p></td><td style="vertical-align:top"><p>Alfentanil AUC0-&infin; 6-fold</p></td><td style="vertical-align:top"><p>alfentanil and metabolised by</p></td></tr><tr><td style="vertical-align:top"><p>naloxone)</p></td><td style="vertical-align:top"><p>In an independent published study,</p></td><td style="vertical-align:top"><p>CYP3A4&nbsp; (e.g.,&nbsp; sufentanil)</p></td></tr><tr><td style="vertical-align:top"><p>Fentanyl (5 mg/kg single dose)</p></td><td style="vertical-align:top"><p>Fentanyl AUC0-&infin; 1.34-fold</p></td><td style="vertical-align:top"><p>should be considered. Extended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>and frequent monitoring for</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>respiratory depression and other</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>opiate-associated adverse reactions is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Statins (e.g., lovastatin)</p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is</p></td><td style="vertical-align:top"><p>If concomitant</p></td></tr><tr><td style="vertical-align:top"><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>likely&nbsp; to&nbsp; increase&nbsp; the&nbsp; plasma</p></td><td style="vertical-align:top"><p>administration of</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>concentrations of statins that are</p></td><td style="vertical-align:top"><p>voriconazole with</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>metabolised by CYP3A4 and could</p></td><td style="vertical-align:top"><p>statins</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>lead to rhabdomyolysis.</p></td><td style="vertical-align:top"><p>metabolised by</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>CYP3A4 cannot be</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>avoided, dose</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>reduction of the</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>statin should be</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>considered.</p></td></tr><tr><td style="vertical-align:top"><p>Sulphonylureas (e.g.,</p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is</p></td><td style="vertical-align:top"><p>Careful monitoring of blood</p></td></tr><tr><td style="vertical-align:top"><p>tolbutamide, glipizide,</p></td><td style="vertical-align:top"><p>likely&nbsp; to&nbsp; increase&nbsp; the&nbsp; plasma</p></td><td style="vertical-align:top"><p>glucose is recommended. Dose</p></td></tr><tr><td style="vertical-align:top"><p>glyburide)</p></td><td style="vertical-align:top"><p>concentrations of sulphonylureas and</p></td><td style="vertical-align:top"><p>reduction&nbsp; of&nbsp; sulfonylureas</p></td></tr><tr><td style="vertical-align:top"><p><em>[CYP2C9 substrates]</em></p></td><td style="vertical-align:top"><p>cause hypoglycaemia.</p></td><td style="vertical-align:top"><p>should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Vinca Alkaloids (e.g.,</p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is</p></td><td style="vertical-align:top"><p>Dose&nbsp; reduction&nbsp; of&nbsp; vinca</p></td></tr><tr><td style="vertical-align:top"><p>vincristine and vinblastine)</p></td><td style="vertical-align:top"><p>likely&nbsp; to&nbsp; increase&nbsp; the&nbsp; plasma</p></td><td style="vertical-align:top"><p>alkaloids should be considered.</p></td></tr><tr><td style="vertical-align:top"><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>concentrations of vinca alkaloids and</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>lead to neurotoxicity.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Other HIV Protease Inhibitors</p></td><td style="vertical-align:top"><p>Not studied clinically. <em>In vitro </em>studies</p></td><td style="vertical-align:top"><p>Careful monitoring for any</p></td></tr><tr><td style="vertical-align:top"><p>(e.g., saquinavir, amprenavir</p></td><td style="vertical-align:top"><p>show that voriconazole may inhibit</p></td><td style="vertical-align:top"><p>occurrence of drug toxicity</p></td></tr><tr><td style="vertical-align:top"><p>and nelfinavir)<sup>*</sup></p></td><td style="vertical-align:top"><p>the metabolism of HIV protease</p></td><td style="vertical-align:top"><p>and/or lack of efficacy, and dose</p></td></tr><tr><td style="vertical-align:top"><p><em>[CYP3A4 substrates and</em></p></td><td style="vertical-align:top"><p>inhibitors and the metabolism of</p></td><td style="vertical-align:top"><p>adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p><em>inhibitors]</em></p></td><td style="vertical-align:top"><p>voriconazole may also be inhibited</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>by HIV protease inhibitors.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Other Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (e.g., delavirdine, nevirapine)<sup>*</sup></p><p><em>[CYP3A4 substrates, inhibitors or CYP450 inducers]</em></p></td><td style="vertical-align:top"><p>Not studied clinically. <em>In</em><em> </em><em>vitro</em><em> </em>studies show that the metabolism of voriconazole may be inhibited by NNRTIs and voriconazole may inhibit the metabolism of NNRTIs. The findings of the effect of efavirenz on voriconazole suggest that the metabolism of voriconazole may be induced by an NNRTI.</p></td><td style="vertical-align:top"><p>Careful monitoring for any occurrence of drug toxicity and/or lack of efficacy, and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Tretinoin</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole may increase tretinoin concentrations and increase risk of adverse reactions (pseudotumor cerebri, hypercalcaemia).</p></td><td style="vertical-align:top"><p>Dose adjustment of tretinoin is recommended during treatment with voriconazole and after its discontinuation.</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine (400 mg BID)</p><p><em>[non-specific CYP450 inhibitor and increases gastric pH]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax 18%</p><p>Voriconazole AUC 23%</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin (0.25 mg QD)</p><p><em>[P-gp substrate]</em></p></td><td style="vertical-align:top"><p>Digoxin Cmax &harr; Digoxin AUC &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir (800 mg TID)</p></td><td style="vertical-align:top"><p>Indinavir Cmax &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p><em>[CYP3A4 inhibitor and</em></p></td><td style="vertical-align:top"><p>Indinavir AUC &harr;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>substrate]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax &harr;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Voriconazole AUC &harr;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Macrolide antibiotics Erythromycin (1 g BID) <em>[CYP3A4 inhibitor] </em>Azithromycin (500 mg QD)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Voriconazole Cmax and AUC &harr;</p><p>Voriconazole Cmax and AUC &harr; The effect of voriconazole on either erythromycin or azithromycin is unknown.</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Mycophenolic acid (1 g single dose)</p><p><em>[UDP-glucuronyl transferase substrate]</em></p></td><td style="vertical-align:top"><p>Mycophenolic acid Cmax &harr; Mycophenolic acid AUCt &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Corticosteroids</p><p>&nbsp;</p><p>Prednisolone (60 mg single dose)</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Prednisolone Cmax 11%</p><p>Prednisolone AUC0-&infin; 34%</p></td><td style="vertical-align:top"><p>No dose adjustment</p><p>&nbsp;</p><p>Patients on long-term treatment with voriconazole</p><p>and corticosteroids (including inhaled corticosteroids e.g., budesonide and intranasal corticosteroids) should be carefully monitored for adrenal cortex dysfunction both during treatment and when voriconazole is discontinued.</p></td></tr><tr><td style="vertical-align:top"><p>Ranitidine (150 mg BID)</p><p><em>[increases gastric pH]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax and AUC &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate data on the use of voriconazole in pregnant women available.</p><p>Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown.</p><p>&nbsp;</p><p>Voriconazole must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Women of child-bearing potential</u></p><p>Women of child-bearing potential must always use effective contraception during treatment.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>The excretion of voriconazole into breast milk has not been investigated. Breast-feeding must be stopped on initiation of treatment with voriconazole.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In an animal study, no impairment of fertility was demonstrated in male and female rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voriconazole has moderate influence on the ability to drive and use machines. It may cause transient and reversible changes to vision, including blurring, altered/enhanced visual perception and/or photophobia. Patients must avoid potentially hazardous tasks, such as driving or operating machinery while experiencing these symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>The safety profile of voriconazole in adults is based on an integrated safety database of more than 2,000 subjects (including 1,603 adult patients in therapeutic trials) and an additional 270 adults in prophylaxis trials. This represents a heterogeneous population, containing patients with haematological malignancy, HIV- infected patients with oesophageal candidiasis and refractory fungal infections, non-neutropenic patients with candidaemia or aspergillosis and healthy volunteers.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions were visual disturbances, pyrexia, rash, vomiting, nausea, diarrhoea, headache, peripheral oedema, liver function test abnormal, respiratory distress and abdominal pain.</p><p>&nbsp;</p><p>The severity of the adverse reactions was generally mild to moderate. No clinically significant differences were seen when the safety data were analysed by age, race, or gender.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>In the table below, since the majority of the studies were of an open nature, all causality adverse reactions and their frequency categories in 1,873 adults from pooled therapeutic (1,603) and prophylaxis (270) studies, by system organ class, are listed.</p><p>&nbsp;</p><p>Frequency categories are expressed as: Very common (&ge;1/10); Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Undesirable effects reported in subjects receiving voriconazole:</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very Common</p><p>&ge; 1/10</p></td><td style="vertical-align:top"><p>Common</p><p>&ge; 1/100 to &lt; 1/10</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&ge; 1/1,000 to &lt; 1/100</p></td><td style="vertical-align:top"><p>Rare</p><p>&ge; 1/10,000 to</p><p>&lt; 1/1,000</p></td><td style="vertical-align:top"><p>Frequency not known (cannot be estimated from</p><p>available data)</p></td></tr><tr><td style="vertical-align:top"><p>Infections and Infestation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>sinusitis</p></td><td style="vertical-align:top"><p>Pseudomembrano us colitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Neoplasms Benign, Malignant and Unspecified (including</p><p>cysts and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Squamous cell carcinoma*</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis<sup>1</sup>, pancytopenia, thrombocytopenia <sup>2</sup>,&nbsp; leukopenia,</p><p>anaemia</p></td><td style="vertical-align:top"><p>bone marrow failure, lymphadenopathy</p><p>, eosinophilia</p></td><td style="vertical-align:top"><p>Disseminated intravascular coagulation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Anaphylactoid reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Adrenal</p><p>insufficiency, hypothyroidism</p></td><td style="vertical-align:top"><p>Hyperthyroidis m</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>Hypoglycaemia, hypokalaemia, hyponatraemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression, hallucination, anxiety, insomnia, agitation,</p><p>confusional state</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Convulsion, syncope, tremor, hypertonia<sup>3</sup>, paraesthesia, somnolence, dizziness</p></td><td style="vertical-align:top"><p>Brain oedema, encephalopathy<sup>4</sup>, extrapyramidal disorder<sup>5</sup>, neuropathy peripheral, ataxia,</p><p>hypoaesthesia, dysgeusia</p></td><td style="vertical-align:top"><p>Hepatic encephalopath y, Guillain- Barre syndrome, nystagmus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Visual impairmen t6</p></td><td style="vertical-align:top"><p>Retinal haemorrhage</p></td><td style="vertical-align:top"><p>Optic nerve disorder<sup>7</sup>, Papilloedema<sup>8</sup>, Oculogyric crisis, diplopia,</p><p>scleritis, blepharitis</p></td><td style="vertical-align:top"><p>Optic atrophy, corneal opacity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear&nbsp;&nbsp; and</p><p>labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypoacusis, vertigo, tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arrhythmia supraventricular, tachycardia, bradycardia</p></td><td style="vertical-align:top"><p>Ventricular fibrillation, ventricular extrasystoles, ventricular tachycardia electrocardiogram QT</p><p>prolonged,suprav</p></td><td style="vertical-align:top"><p>Torsades de pointes, atrioventricula r&nbsp;&nbsp;&nbsp; block</p><p>complete, bundle branch block, nodal rhythm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>entricular</p><p>tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension,</p><p>phlebitis</p></td><td style="vertical-align:top"><p>Thrombophlebitis</p><p>, lymphangitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>Respirator y distress<sup>9</sup></p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome, pulmonary</p><p>oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestin al disorders</p></td><td style="vertical-align:top"><p>Diarrhoea, vomiting, abdominal pain, nausea</p></td><td style="vertical-align:top"><p>Cheilitis, dyspepsia, constipation, gingivitis</p></td><td style="vertical-align:top"><p>Peritonitis, pancreatitis, swollen tongue, duodenitis, gastroenteritis,</p><p>glossitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepato- biliary disorders</p></td><td style="vertical-align:top"><p>Liver function test abnormal</p></td><td style="vertical-align:top"><p>Jaundice, jaundice cholestatic, hepatitis<sup>10</sup></p></td><td style="vertical-align:top"><p>Hepatic failure, hepatomegaly, cholecystitis, cholelithiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Dermatitis exfoliative, alopecia, rash maculo-papular, pruritus, erythema</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, phototoxicity, purpura, urticaria, dermatitis allergic,</p><p>rash papular,</p><p>rash macular, eczema</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis, angioedema, actinic keratosis*, pseudoporphyr ia erythema multiforme, psoriasis, drug</p><p>eruption</p></td><td style="vertical-align:top"><p>Cutaneous lupus erythemato sis* ephelides*, lentigo*</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskele tal&nbsp;&nbsp;&nbsp; and</p><p>connective</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Arthritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Periostitis*</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal failure acute, haematuria</p></td><td style="vertical-align:top"><p>Renal tubular necrosis, proteinuria,</p><p>nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administratio n&nbsp;&nbsp;&nbsp; site</p><p>conditions</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Chest pain, face oedema<sup>11</sup>, asthenia, chills</p></td><td style="vertical-align:top"><p>Infusionsite reaction, influenza like illness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Blood urea increased, blood cholesterol</p><p>increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*ADR identified post-marketing</p><p>1 Includes febrile neutropenia and neutropenia.</p><p>2 Includes immune thrombocytopenic purpura.</p><p>3 Includes nuchal rigidity and tetany.</p><p>4 Includes hypoxic-ischaemic encephalopathy and metabolic encephalopathy.</p><p>5 Includes akathisia and parkinsonism.</p><p>6 See &ldquo;Visual impairments&rdquo; paragraph in section 4.8.</p><p>7 Prolonged optic neuritis has been reported post-marketing. See section 4.4.</p><p>8 See section 4.4.</p><p>9 Includes dyspnoea and dyspnoea exertional.</p><p>10 Includes drug-induced liver injury, hepatitis toxic, hepatocellular injury and hepatotoxicity.</p><p>11 Includes periorbital oedema, lip oedema, and oedema mouth.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Altered taste perception</em></p><p><em>&nbsp;</em></p><p>In the combined data from three bioequivalence studies using the powder for oral suspension formulation, treatment-related taste perversion was recorded in 12 (14%) of subjects.</p><p>&nbsp;</p><p><em>Visual impairments</em></p><p><em>&nbsp;</em></p><p>In clinical trials, visual impairments (including blurred vision, photophobia, chloropsia, chromatopsia, colour blindness, cyanopsia, eye disorder, halo vision, night blindness, oscillopsia, photopsia, scintillating scotoma, visual acuity reduced, visual brightness, visual field defect, vitreous floaters, and xanthopsia) with voriconazole were very common. These visual impairments were transient and fully reversible, with the majority spontaneously resolving within 60 minutes and no clinically significant long-term visual effects were observed. There was evidence of attenuation with repeated doses of voriconazole. The visual disturbances were generally mild, rarely resulted in discontinuation and were not associated with long-term sequelae. Visual disturbances may be associated with higher plasma concentrations and/or doses.</p><p>&nbsp;</p><p>The mechanism of action is unknown, although the site of action is most likely to be within the retina. In a study in healthy volunteers investigating the impact of voriconazole on retinal function, voriconazole caused a decrease in the electroretinogram (ERG) waveform amplitude. The ERG measures electrical currents in the retina. The ERG changes did not progress over 29 days of treatment and were fully reversible on withdrawal of voriconazole.</p><p>&nbsp;</p><p>There have been post-marketing reports of prolonged visual adverse events.</p><p>&nbsp;</p><p><em>Dermatological reactions</em></p><p><em>&nbsp;</em></p><p>Dermatological reactions were common in patients treated with voriconazole in clinical trials, but these patients had serious underlying diseases and were receiving multiple concomitant medicinal products. The majority of rashes were of mild to moderate severity. Patients have rarely developed serious cutaneous reactions, including Stevens-Johnson syndrome (uncommon), toxic epidermal necrolysis (rare) and erythema multiforme (rare) during treatment with voriconazole.</p><p>&nbsp;</p><p>If a patient develops a rash they should be monitored closely and voriconazole discontinued if lesions progress. Photosensitivity reactions such as ephelides, lentigo and actinic keratosis have been reported, especially during long-term therapy.</p><p>&nbsp;</p><p>There have been reports of squamous cell carcinoma of the skin in patients treated with voriconazole for long periods of time; the mechanism has not been established.</p><p>&nbsp;</p><p><em>Liver function tests</em></p><p><em>&nbsp;</em>The overall incidence of transaminase increases &gt;3 xULN (not necessarily comprising an adverse event)in the voriconazole clinical programme was 18 % (319/1,768) in adults and 25.8% (73/283) in paediatric subjects who received voriconazole for pooled therapeutic and prophylaxis use Liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of abnormal liver function tests either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.</p><p>&nbsp;</p><p>Voriconazole has been associated with cases of serious hepatic toxicity in patients with other serious underlying conditions. This includes cases of jaundice, hepatitis and hepatic failure leading to death.</p><p><em>Prophylaxis</em></p><p><em>&nbsp;</em>In an open-label, comparative, multicenter study comparing voriconazole and itraconazole as primary prophylaxis in adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI, permanent discontinuation of voriconazole due to AEs was reported in 39.3% of subjects versus 39.6% of subjects in the itraconazole arm. Treatment-emergent hepatic AEs resulted in permanent discontinuation of study medication for 50 subjects (21.4%) treated with voriconazole and for 18 subjects (7.1%) treated with itraconazole.</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em>The safety of voriconazole was investigated in 288 paediatric patients aged 2 to &lt;12 years</p><p>(169) and 12 to &lt;18 years (119) who received voriconazole for prophylaxis (183) and therapeutic use (105) in clinical trials. The safety of voriconazole was also investigated in 158 additional paediatric patients aged 2 to &lt;12 years in compassionate use programs. Overall the safety profile of voriconazole in paediatric population was similar to that in adults. However, a trend towards a higher frequency of liver enzyme elevations, reported as adverse events in clinical trials was observed in paediatric patients as compared to adults (14.2% transaminases increased in paediatrics compared to 5.3% in adults). Post-marketing data suggest there might be a higher occurrence of skin reactions (especially erythema) in the paediatric population compared to adults. In the 22 patients less than 2 years old who received voriconazole in a compassionate use programme, the following adverse reactions (for which a relationship to voriconazole could not be excluded) were reported: photosensitivity reaction (1), arrhythmia (1), pancreatitis (1), blood bilirubin increased (1), hepatic enzymes increased (1), rash (1) and papilloedema (1). There have been post- marketing reports of pancreatitis in paediatric patients.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><strong>To report any side effect(s):</strong></p><p>&sect;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><p><strong><em>&nbsp;</em></strong>The National Pharmacovigilance Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa</u></p><p>&sect;&nbsp;&nbsp; <strong><em>Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials there were 3 cases of accidental overdose. All occurred in paediatric patients, who received up to five times the recommended intravenous dose of voriconazole. A single adverse reaction of photophobia of 10 minutes duration was reported.</p><p>There is no known antidote to voriconazole.</p><p>Voriconazole is haemodialysed with a clearance of 121 ml/min. In an overdose, haemodialysis may assist in the removal of voriconazole from the body.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>Antimycotics for systemic use, triazole derivatives</p><p>&nbsp;</p><p><strong>ATC code: </strong>J02 AC03</p><p>&nbsp;</p><p><u>Mode of Action</u></p><p>&nbsp;</p><p>Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of voriconazole. Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic Relationship</u></p><p>&nbsp;</p><p>In 10 therapeutic studies, the median for the average and maximum plasma concentrations in individual subjects across the studies was 2425 ng/ml (inter-quartile range 1193 to 4380 ng/ml) and 3742 ng/ml (inter-quartile range 2027 to 6302 ng/ml), respectively. A positive association between mean, maximum or minimum plasma voriconazole concentration and efficacy in therapeutic studies was not found and this relationship has not been explored in prophylaxis studies.</p><p>&nbsp;</p><p>Pharmacokinetic-Pharmacodynamic analyses of clinical trial data identified positive associations between plasma voriconazole concentrations and both liver function test</p><p>&nbsp;</p><p>abnormalities and visual disturbances. Dose adjustments in prophylaxis studies have not been explored.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>In vitro</em>, voriconazole displays broad-spectrum antifungal activity with antifungal potency against <em>Candida </em>species (including fluconazole- resistant C. <em>krusei </em>and resistant strains of C. <em>glabrata </em>and C. <em>albicans</em>) and fungicidal activity against all <em>Aspergillus </em>species tested. In addition voriconazole shows in vitro fungicidal activity against emerging fungal pathogens, including those such as <em>Scedosporium </em>or <em>Fusarium </em>which have limited susceptibility to existing antifungal agents.</p><p>&nbsp;</p><p>Clinical efficacy defined as partial or complete response, has been demonstrated for <em>Aspergillus </em>spp. including A. <em>flavus</em>, A. <em>fumigatus</em>, A. <em>terreus</em>, A. <em>niger</em>, A. <em>nidulans</em>; <em>Candida </em>spp., including C. <em>albicans</em>, C. <em>glabrata</em>, C. <em>krusei</em>, C. <em>parapsilosis </em>and C. <em>tropicalis</em>; and limited numbers of C. <em>dubliniensis</em>, C. <em>inconspicua </em>and C. <em>guilliermondii</em>, <em>Scedosporium </em>spp., including S. <em>apiospermum</em>, S. <em>prolificans</em>; and <em>Fusarium </em>spp.</p><p>&nbsp;</p><p>Other treated fungal infections (often with either partial or complete response) included isolated cases of <em>Alternaria </em>spp., <em>Blastomyces dermatitidis, Blastoschizomyces capitatus, Cladosporium&nbsp; </em>spp.,&nbsp; <em>Coccidioides&nbsp; immitis,&nbsp; Conidiobolus&nbsp; coronatus,&nbsp; Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, Penicillium </em>spp. including <em>P. marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis </em>and <em>Trichosporon </em>spp. including <em>T. beigelii </em>infections.</p><p>&nbsp;</p><p><em>In vitro </em>activity against clinical isolates has been observed for <em>Acremonium </em>spp., <em>Alternaria </em>spp., <em>Bipolaris </em>spp., <em>Cladophialophora </em>spp., and <em>Histoplasma capsulatum</em>, with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 &mu;g/ml.</p><p><em>In vitro </em>activity against the following pathogens has been shown, but the clinical significance is unknown: <em>Curvularia </em>spp. and <em>Sporothrix </em>spp.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>&nbsp;</p><p>Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.</p><p>The species most frequently involved in causing human infections include <em>C. albicans</em>, <em>C. parapsilosis, C. tropicalis, C. glabrata </em>and <em>C. krusei</em>, all of which usually exhibit minimal inhibitory concentration (MICs) of less than 1 mg/L for voriconazole.</p><p>&nbsp;</p><p>However, the <em>in vitro </em>activity of voriconazole against <em>Candida </em>species is not uniform. Specifically, for <em>C. glabrata</em>, the MICs of voriconazole for fluconazole-resistant isolates are proportionally higher than are those of fluconazole-susceptible isolates. Therefore, every attempt should be made to identify <em>Candida </em>to species level. If antifungal susceptibility testing is available, the MIC results may be interpreted using breakpoint criteria established by European Committee on Antimicrobial Susceptibility Testing (EUCAST).</p><p>&nbsp;</p><p>EUCAST Breakpoints</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Candida species</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MIC breakpoint (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&le;S (Susceptible)</strong></p></td><td style="vertical-align:top"><p><strong>&gt;R (Resistant)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Candida albicans<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.125</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida tropicalis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.125</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida parapsilosis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.125</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida glabrata<strong><sup>2</sup></strong></em></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida krusei<strong><sup>3</sup></strong></em></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td style="vertical-align:top"><p><em>Other Candida spp.<strong><sup>4</sup></strong></em></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>1 </strong>Strains with MIC values above the Susceptible (S) breakpoint are rare, or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory.</p><p><strong>2 </strong>In clinical studies, response to voriconazole in patients with <em>C. glabrata </em>infections was 21% lower compared to <em>C. albicans, C. parapsilosis and C. tropicalis. In vitro </em>data showed a slight increase of resistance of <em>C. glabrata </em>to voriconazole.</p><p><strong>3 </strong>In clinical studies, response to voriconazole in <em>C. krusei </em>infections was similar to <em>C. albicans, C. parapsilosis and C. tropicalis. </em>However, as there were only 9 cases available for EUCAST analysis, there is currently insufficient evidence to set clinical breakpoints for <em>C. krusei</em>.</p><p><strong>4 </strong>EUCAST has not determined non-species related breakpoints for voriconazole</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Clinical experience</u></p><p>Successful outcome in this section is defined as complete or partial response.</p><p>&nbsp;</p><p><em><u>Aspergillus </u></em><u>infections &ndash; efficacy in aspergillosis patients with poor prognosis</u></p><p>Voriconazole has <em>in vitro </em>fungicidal activity against <em>Aspergillus </em>spp. The efficacy and survival benefit of voriconazole versus conventional amphotericin B in the primary treatment of acute invasive aspergillosis was demonstrated in an open, randomised, multicentre study in 277 immunocompromised patients treated for 12 weeks. Voriconazole was administered intravenously with a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours for a minimum of 7 days. Therapy could then be switched to the oral formulation at a dose of 200 mg every 12 hours. Median duration of IV voriconazole therapy was 10 days (range 2-85 days). After IV voriconazole therapy, the median duration of oral voriconazole therapy was 76 days (range 2-232 days).</p><p>&nbsp;</p><p>A satisfactory global response (complete or partial resolution of all attributable symptoms, signs, radiographic/bronchoscopic abnormalities present at baseline) was seen in 53% of voriconazole-treated patientscompared to 31% of patients treated with comparator. The 84- day survival rate for voriconazole was statistically significantly higher than that for the comparator and a clinically and statistically significant benefit was shown in favour of voriconazole for both time to death and time to discontinuation due to toxicity.</p><p>&nbsp;</p><p>This study confirmed findings from an earlier, prospectively designed study where there was a positive outcome in subjects with risk factors for a poor prognosis, including graft versus host disease, and, in particular, cerebral infections (normally associated with almost 100 % mortality).</p><p>The studies included cerebral, sinus, pulmonary and disseminated aspergillosis in patients with bone marrow and solid organ transplants, haematological malignancies, cancer and AIDS.</p><p><u>Candidaemia in non-neutropenic patients</u></p><p>&nbsp;</p><p>The efficacy of voriconazole compared to the regimen of amphotericin B followed by fluconazole in the primary treatment of candidaemia was demonstrated in an open, comparative study. Three hundred and seventy non-neutropenic patients (above 12 years of age) with documented candidaemia were included in the study, of whom 248 were treated with voriconazole. Nine subjects in the voriconazole group and 5 in the amphotericin B followed by fluconazole group also had mycologically proven infection in deep tissue. Patients with renal failure were excluded from this study. The median treatment duration was 15 days in both treatment arms. In the primary analysis, successful response as assessed by a Data Review Committee (DRC) blinded to study medicinal product was defined as resolution/improvement in all clinical signs and symptoms of infection with eradication of <em>Candida </em>from blood and infected deep tissue sites 12 weeks after the end of therapy (EOT). Patients who did not have an assessment 12 weeks after EOT were counted as failures. In this analysis a successful response was seen in 41% of patients in both treatment arms.</p><p>&nbsp;</p><p>In a secondary analysis, which utilised DRC assessments at the latest evaluable time point (EOT, or 2, 6, or 12 weeks after EOT) voriconazole and the regimen of amphotericin B followed by fluconazole had successful response rates of 65% and 71%, respectively. The Investigator&#39;s assessment of successful outcome at each of these time points is shown in the following table.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Timepoint</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Voriconazole (N=248)</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Amphotericin B &rarr; fluconazole (N=122)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>EOT</p></td><td style="vertical-align:top"><p>178 (72%)</p></td><td style="vertical-align:top"><p>88 (72%)</p></td></tr><tr><td style="vertical-align:top"><p>2 weeks after EOT</p></td><td style="vertical-align:top"><p>125 (50%)</p></td><td style="vertical-align:top"><p>62 (51%)</p></td></tr><tr><td style="vertical-align:top"><p>6 weeks after EOT</p></td><td style="vertical-align:top"><p>104 (42%)</p></td><td style="vertical-align:top"><p>55 (45%)</p></td></tr><tr><td style="vertical-align:top"><p>12 weeks after EOT</p></td><td style="vertical-align:top"><p>104 (42%)</p></td><td style="vertical-align:top"><p>51 (42%)</p></td></tr></tbody></table><p><u>Serious refractory <em>Candida </em>infections</u></p><p>The study comprised 55 patients with serious refractory systemic <em>Candida </em>infections (including candidaemia, disseminated and other invasive candidiasis) where prior antifungal treatment, particularly with fluconazole, had been ineffective. Successful response was seen in 24 patients (15 complete, 9 partial responses). In fluconazole-resistant non-<em>albicans </em>species, a successful outcome was seen in 3/3 <em>C. krusei </em>(complete responses) and 6/8 <em>C. glabrata </em>(5 complete, 1 partial response) infections. The clinical efficacy data were supported by limited susceptibility data.</p><p>&nbsp;</p><p><em><u>Scedosporium </u></em><u>and <em>Fusarium </em>infections</u></p><p>Voriconazole was shown to be effective against the following rare fungal pathogens: <em>Scedosporium </em>spp.: Successful response to voriconazole therapy was seen in 16 (6 complete, 10 partial responses) of 28 patients with <em>S. apiospermum </em>and in 2 (both partial responses) of 7 patients with <em>S. prolificans </em>infection. In addition, a successful response was seen in 1 of 3 patients with infections caused by more than one organism including <em>Scedosporium </em>spp.</p><p>&nbsp;</p><p><em>Fusarium </em>spp.: Seven (3 complete, 4 partial responses) of 17 patients were successfully treated with voriconazole. Of these 7 patients, 3 had eye, 1 had sinus, and 3 had disseminated infection. Four additional patients with fusariosis had an infection caused by several organisms; 2 of them had a successful outcome.</p><p>&nbsp;</p><p>The majority of patients receiving voriconazole treatment of the above mentioned rare infections were intolerant of, or refractory to, prior antifungal therapy.</p><p>&nbsp;</p><p><u>Primary Prophylaxis of Invasive Fungal Infections &ndash; Efficacy in HSCT recipients without</u> <u>prior proven or probable IFI</u></p><p>Voriconazole was compared to itraconazole as primary prophylaxis in an open-label, comparative, multicenter study of adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI. Success was defined as the ability to continue study drug prophylaxis for 100 days after HSCT (without stopping for &gt;14 days) and survival with no proven or probable IFI for 180 days after HSCT. The modified intent-to-treat (MITT) group included 465 allogeneic HSCT recipients with 45% of patients having AML. From all patients 58% were subject to myeloablative conditions regimens.</p><p>&nbsp;</p><p>Prophylaxis with study drug was started immediately after HSCT: 224 received voriconazole and 241 received itraconazole. The median duration of study drug prophylaxis was 96 days for voriconazole and 68 days for itraconazole in the MITT group.</p><p>&nbsp;</p><p>Success rates and other secondary endpoints are presented in the table below:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study Endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole </strong><strong>N=224</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole </strong><strong>N=241</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions</strong></p><p><strong>and the 95% confidence</strong></p><p><strong>interval (CI)</strong></p></td><td style="vertical-align:top"><p><strong>P-Value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Success at day 180*</p></td><td style="vertical-align:top"><p>109 (48.7%)</p></td><td style="vertical-align:top"><p>80 (33.2%)</p></td><td style="vertical-align:top"><p>16.4% (7.7%, 25.1%)**</p></td><td style="vertical-align:top"><p>0.0002**</p></td></tr><tr><td style="vertical-align:top"><p>Success at day 100</p></td><td style="vertical-align:top"><p>121 (54.0%)</p></td><td style="vertical-align:top"><p>96 (39.8%)</p></td><td style="vertical-align:top"><p>15.4% (6.6%, 24.2%)**</p></td><td style="vertical-align:top"><p>0.0006**</p></td></tr><tr><td style="vertical-align:top"><p>Completed at least 100 days</p><p>of study drug prophylaxis</p></td><td style="vertical-align:top"><p>120 (53.6%)</p></td><td style="vertical-align:top"><p>94 (39.0%)</p></td><td style="vertical-align:top"><p>14.6% (5.6%, 23.5%)</p></td><td style="vertical-align:top"><p>0.0015</p></td></tr><tr><td style="vertical-align:top"><p>Survived to day</p></td><td style="vertical-align:top"><p>184 (82.1%)</p></td><td style="vertical-align:top"><p>197 (81.7%)</p></td><td style="vertical-align:top"><p>180 0.4% (-6.6%, 7.4%)</p></td><td style="vertical-align:top"><p>0.9107</p></td></tr><tr><td style="vertical-align:top"><p>Developed&nbsp; proven&nbsp; or</p><p>probable IFI to day 180</p></td><td style="vertical-align:top"><p>3 (1.3%)</p></td><td style="vertical-align:top"><p>5 (2.1%)</p></td><td style="vertical-align:top"><p>-0.7% (-3.1%, 1.6%)</p></td><td style="vertical-align:top"><p>0.5390</p></td></tr><tr><td style="vertical-align:top"><p>Developed&nbsp; proven&nbsp; or</p><p>probable IFI to day 100</p></td><td style="vertical-align:top"><p>2 (0.9%)</p></td><td style="vertical-align:top"><p>4 (1.7%)</p></td><td style="vertical-align:top"><p>-0.8% (-2.8%, 1.3%)</p></td><td style="vertical-align:top"><p>0.4589</p></td></tr><tr><td style="vertical-align:top"><p>Developed&nbsp; proven&nbsp; or</p><p>probable IFI while on study drug</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3 (1.2%)</p></td><td style="vertical-align:top"><p>-1.2% (-2.6%, 0.2%)</p></td><td style="vertical-align:top"><p>0.0813</p></td></tr></tbody></table><p>* Primary endpoint of the study</p><p>** Difference in proportions, 95% CI and p-values obtained after adjustment for randomization</p><p>&nbsp;</p><p>The breakthrough IFI rate to Day 180 and the primary endpoint of the study, which is Success at Day 180, for patients with AML and myeloablative conditioning regimens respectively, is presented in the table below:</p><p>&nbsp;</p><p><strong>AML</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole (N=98)</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole (N=109)</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and the 95% confidence interval (CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Breakthrough IFI &ndash; Day 180</p></td><td style="vertical-align:top"><p>1 (1.0%)</p></td><td style="vertical-align:top"><p>2 (1.8%)</p></td><td style="vertical-align:top"><p>-0.8% (-4.0%, 2.4%) **</p></td></tr><tr><td style="vertical-align:top"><p>Success at Day 180*</p></td><td style="vertical-align:top"><p>55 (56.1%)</p></td><td style="vertical-align:top"><p>45 (41.3%)</p></td><td style="vertical-align:top"><p>14.7% (1.7%, 27.7%)***</p></td></tr></tbody></table><p>* Primary endpoint of study</p><p>** Using a margin of 5%, non inferiority is demonstrated</p><p>***Difference in proportions, 95% CI obtained after adjustment for randomization</p><p>&nbsp;</p><p><strong>Myeloablative conditioning regimens</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole (N=125)</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole (N=143)</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and the 95% confidence interval (CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Breakthrough IFI &ndash; Day 180</p></td><td style="vertical-align:top"><p>2 (1.6%)</p></td><td style="vertical-align:top"><p>3 (2.1%)</p></td><td style="vertical-align:top"><p>-0.5% (-3.7%, 2.7%) **</p></td></tr><tr><td style="vertical-align:top"><p>Success at Day 180*</p></td><td style="vertical-align:top"><p>70 (56.0%)</p></td><td style="vertical-align:top"><p>53 (37.1%)</p></td><td style="vertical-align:top"><p>20.1% (8.5%, 31.7%)***</p></td></tr></tbody></table><p>* Primary endpoint of study</p><p>** Using a margin of 5%, non inferiority is demonstrated</p><p>*** Difference in proportions, 95% CI obtained after adjustment for randomization</p><p>&nbsp;</p><p><u>Secondary Prophylaxis of IFI &ndash; Efficacy in HSCT recipients with prior proven or probable</u> <u>IFI</u></p><p>Voriconazole was investigated as secondary prophylaxis in an open-label, non-comparative, multicentre study of adult allogeneic HSCT recipients with prior proven or probable IFI. The primary endpoint was the rate of occurrence of proven and probable IFI during the first year after HSCT. The MITT group included 40 patients with prior IFI, including 31 with aspergillosis, 5 with candidiasis, and 4 with other IFI. The median duration of study drug prophylaxis was 95.5 days in the MITT group.</p><p>&nbsp;</p><p>Proven or probable IFIs developed in 7.5% (3/40) of patients during the first year after HSCT, including one candidemia, one scedosporiosis (both relapses of prior IFI), and one zygomycosis. The survival rate at Day 180 was 80.0% (32/40) and at 1 year was 70.0% (28/40).</p><p>&nbsp;</p><p><u>Duration of treatment</u></p><p>In clinical trials, 705 patients received voriconazole therapy for greater than 12 weeks, with 164 patients receiving voriconazole for over 6 months.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Fifty-three paediatric patients aged 2 to &lt;18 years were treated with voriconazole in two prospective, open-label, noncomparative, multi-centre clinical trials. One study enrolled 31 patients with possible, proven or probable invasive aspergillosis (IA), of whom 14 patients had proven or probable IA and were included in the MITT efficacy analyses. The second study enrolled 22 patients with invasive candidiasis including candidaemia (ICC), and oesophageal candidiasis (EC) requiring either primary or salvage therapy, of whom 17 were included in the MITT efficacy analyses. For patients with IA the overall rates of global response at 6 weeks were 64.3% (9/14), the global response rate was 40% (2/5) for patients 2 to &lt;12 years and 77.8% (7/9) for patients 12 to &lt;18 years of age. For patients with ICC the global response rate at EOT was 85.7% (6/7) and for patients with EC the global response rate at EOT was 70% (7/10). The overall rate of response (ICC and EC combined) was 88.9% (8/9) for 2 to &lt;12 years old and 62.5% (5/8) for 12 to &lt;18 years old.</p><p>&nbsp;</p><p><u>Clinical studies examining QTc interval</u></p><p>A placebo-controlled, randomized, single-dose, crossover study to evaluate the effect on the QTc interval of healthy volunteers was conducted with three oral doses of voriconazole and ketoconazole. The placebo-adjusted mean maximum increases in QTc from baseline after 800, 1200 and 1600 mg of voriconazole were 5.1, 4.8, and 8.2 msec, respectively and 7.0 msec for ketoconazole 800 mg. No subject in any group had an increase in QTc of &ge; 60 msec from baseline. No subject experienced an interval exceeding the potentially clinically- relevant threshold of 500 msec.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General pharmacokinetic characteristics</u></p><p>&nbsp;</p><p>The pharmacokinetics of voriconazole have been characterised in healthy subjects, special populations and patients. During oral administration of 200 mg or 300 mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or haematopoietic tissue), the observed pharmacokinetic characteristics of rapid and consistent absorption, accumulation and non-linear pharmacokinetics were in agreement with those observed in healthy subjects.</p><p>&nbsp;</p><p>The pharmacokinetics of voriconazole are non-linear due to saturation of its metabolism. Greater than proportional increase in exposure is observed with increasing dose. It is estimated that, on average, increasing the oral dose from 200 mg twice daily to 300 mg twice daily leads to a 2.5-fold increase in exposure (AUC). The oral maintenance dose of 200 mg (or 100 mg for patients less than 40 kg) achieves a voriconazole exposure similar to 3 mg/kg</p><p>IV. A 300 mg (or 150 mg for patients less than 40 kg) oral maintenance dose achieves an exposure similar to 4 mg/kg IV. When the recommended intravenous or oral loading dose regimens are administered, plasma concentrations close to steady state are achieved within the first 24 hours of dosing. Without the loading dose, accumulation occurs during twice daily multiple dosing with steady-state plasma voriconazole concentrations being achieved by Day 6 in the majority of subjects.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Voriconazole is rapidly and almost completely absorbed following oral administration, with maximum plasma concentrations (Cmax) achieved 1-2 hours after dosing. The absolute bioavailability of voriconazole after oral administration is estimated to be 96%. When multiple doses of voriconazole are administered with high fat meals, Cmax and AUCt&nbsp;are reduced by 34% and 24%, respectively. The absorption of voriconazole is not affected by changes in gastric pH.</p><p><u>Distribution</u></p><p>The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues. Plasma protein binding is estimated to be 58%. Cerebrospinal fluid samples from eight patients in a compassionate programme showed detectable voriconazole concentrations in all patients.</p><p>&nbsp;</p><p><u>Biotransformation</u><u> </u></p><p><em>In vitro </em>studies showed that voriconazole is metabolised by the hepatic cytochrome P450 isoenzymes CYP2C19, CYP2C9 and CYP3A4.</p><p>The inter-individual variability of voriconazole pharmacokinetics is high.</p><p>&nbsp;</p><p><em>In vivo </em>studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may be expected to be poor metabolisers. For Caucasians and Blacks the prevalence of poor metabolisers is 3-5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolisers have, on average, 4-fold higher voriconazole exposure (AUCt) than their homozygous extensive metaboliser counterparts. Subjects who are heterozygous extensive metabolisers have on average 2-fold higher voriconazole exposure than their homozygous extensive metaboliser counterparts.</p><p>The major metabolite of voriconazole is the N-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma. This metabolite has minimal antifungal activity and does not contribute to the overall efficacy of voriconazole.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.</p><p>&nbsp;</p><p>After administration of a radiolabelled dose of voriconazole, approximately 80% of the radioactivity is recovered in the urine after multiple intravenous dosing and 83% in the urine after multiple oral dosing. The majority (&gt; 94%) of the total radioactivity is excreted in the first 96 hours after both oral and intravenous dosing.</p><p>&nbsp;</p><p>The terminal half-life of voriconazole depends on dose and is approximately 6 hours at 200 mg (orally). Because of non-linear pharmacokinetics, the terminal half-life is not useful in the prediction of the accumulation or elimination of voriconazole.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups</u></p><p>&nbsp;</p><p><u>Gender</u></p><p>In an oral multiple-dose study, Cmax and AUCt&nbsp;for healthy young females were 83% and 113% higher, respectively, than in healthy young males (18-45 years). In the same study, no significant differences in Cmax and AUCt&nbsp;were observed between healthy elderly males and healthy elderly females (&ge; 65 years).</p><p>In the clinical programme, no dosage adjustment was made on the basis of gender. The safety profile and plasma concentrations observed in male and female patients were similar. Therefore, no dosage adjustment based on gender is necessary.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>In an oral multiple-dose study Cmax and AUC&tau; in healthy elderly males (&ge; 65 years) were 61% and 86% higher, respectively, than in healthy young males (18-45 years). No significant differences in Cmax and AUC were observed between healthy elderly females (&ge; 65 years) and healthy young females (18-45 years).</p><p>In the therapeutic studies no dosage adjustment was made on the basis of age. A relationship between plasma concentrations and age was observed. The safety profile of voriconazole in young and elderly patients was similar and, therefore, no dosage adjustment is necessary for the elderly.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The recommended doses in children and adolescent patients are based on a population pharmacokinetic analysis of data obtained from 112 immunocompromised paediatric patients aged 2 to &lt;12 years and 26 immunocompromised adolescent patients aged 12 to &lt;17 years. Multiple intravenous doses of 3, 4, 6, 7 and 8 mg/kg twice daily and multiple oral doses (using the powder for oral suspension) of 4 mg/kg, 6 mg/kg, and 200 mg twice daily were evaluated in 3 paediatric pharmacokinetic studies. Intravenous loading doses of 6 mg/kg IV twice daily on day 1 followed by 4 mg/kg intravenous dose twice daily and 300 mg oral tablets twice daily were evaluated in one adolescent pharmacokinetic study. Larger inter-subject variability was observed in paediatric patients compared to adults.</p><p>&nbsp;</p><p>A comparison of the paediatric and adult population pharmacokinetic data indicated that the predicted total exposure (AUCt) in children following administration of a 9 mg/kg IV loading dose was comparable to that in adults following a 6 mg/kg IV loading dose. The</p><p>predicted total exposures in children following IV maintenance doses of 4 and 8 mg/kg twice daily were comparable to those in adults following 3 and 4 mg/kg IV twice daily, respectively. The predicted total exposure in children following an oral maintenance dose of 9 mg/kg (maximum of 350 mg) twice daily was comparable to that in adults following 200 mg oral twice daily. An 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9 mg/kg oral dose.</p><p>&nbsp;</p><p>The higher intravenous maintenance dose in paediatric patients relative to adults reflects the higher elimination capacity in paediatric patients due to a greater liver mass to body mass ratio. Oral bioavailability may, however, be limited in paediatric patients with malabsorption and very low body weight for their age. In that case, intravenous voriconazole administration is recommended.</p><p>&nbsp;</p><p>Voriconazole exposures in the majority of adolescent patients were comparable to those in adults receiving the same dosing regimens. However, lower voriconazole exposure was observed in some young adolescents with low body weight compared to adults. It is likely that these subjects may metabolize voriconazole more similarly to children than to adults. Based on the population pharmacokinetic analysis, 12- to 14-year-old adolescents weighing less than 50 kg should receive children&#39;s doses.</p><p>&nbsp;</p><p><u>Renal impairment </u></p><p>In an oral single-dose (200 mg) study in subjects with normal renal function and mild (creatinine clearance 41-60 ml/min) to severe (creatinine clearance &lt; 20 ml/min) renal impairment, the pharmacokinetics of voriconazole were not significantly affected by renal impairment. The plasma protein binding of voriconazole was similar in subjects with different degrees of renal impairment.</p><p>&nbsp;</p><p><u>Hepatic impairment </u></p><p>After an oral single-dose (200 mg), AUC was 233% higher in subjects with mild to moderate hepatic cirrhosis (Child-Pugh A and B) compared with subjects with normal hepatic function. Protein binding of voriconazole was not affected by impaired hepatic function.</p><p>In an oral multiple-dose study, AUC&tau; was similar in subjects with moderate hepatic cirrhosis (Child-Pugh B) given a maintenance dose of 100 mg twice daily and subjects with normal hepatic function given 200 mg twice daily. No pharmacokinetic data are available for patients with severe hepatic cirrhosis (Child-Pugh C).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated-dose toxicity studies with voriconazole indicated the liver to be the target organ. Hepatotoxicity occurred at plasma exposures similar to those obtained at therapeutic doses in humans, in common with other antifungal agents. In rats, mice and dogs, voriconazole also induced minimal adrenal changes. Conventional studies of safety pharmacology, genotoxicity or carcinogenic potential did not reveal a special hazard for humans.</p><p>&nbsp;</p><p>In reproduction studies, voriconazole was shown to be teratogenic in rats and embryotoxic in rabbits at systemic exposures equal to those obtained in humans with therapeutic doses. In the pre- and post-natal development study in rats at exposures lower than those obtained in humans with therapeutic doses, voriconazole prolonged the duration of gestation and labour and produced dystocia with consequent maternal mortality and reduced perinatal survival of pups. The effects on parturition are probably mediated by species-specific mechanisms,</p><p>&nbsp;</p><p>involving reduction of oestradiol levels, and are consistent with those observed with other azole antifungal agents. Voriconazole administration induced no impairment of male or female fertility in rats at exposures similar to those obtained in humans at therapeutic doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate (Pharmatose 200 M), Pre-gelatinized Starch, Croscarmellose Sodium, Povidone K-30, Lactose Monohydrate (Supertab 11 SD) Talc, Magnesium Stearate, Opadry II White 32K18425, Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 tablets packed in clear PVC-PVdC/Aluminium blister.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alpha Pharma,Kingdom of Saudi Arabia, RabighP.O. Box 23989-6704Tel: +966 12 21 29013For any information about this medicinal product, please contact the Regulatory affairsdepartment of authorization holder:Regulatory affairs departmentRiyadh, Saudi ArabiaTel: +966112931722 Ex:102 - 104 Email: regulatory@alphapharma.com.saManufacturing site Glenmark Pharmaceuticals Ltd. At: Plot No. 2, Phase –II, Pharma Zone, SEZ, Pithampur, Dist. Dhar Madhya Pradesh – 454775. INDIA.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25/09/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>